<SEC-DOCUMENT>0001193125-23-130656.txt : 20230501
<SEC-HEADER>0001193125-23-130656.hdr.sgml : 20230501
<ACCEPTANCE-DATETIME>20230501170306
ACCESSION NUMBER:		0001193125-23-130656
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230501
DATE AS OF CHANGE:		20230501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		23874817

	BUSINESS ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431
		BUSINESS PHONE:		561-961-1900

	MAIL ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>d497484d10ka.htm
<DESCRIPTION>FORM 10-K/A
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:tmxd="http://www.therapeuticsmd.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>Form 10-K/A</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2022To12_31_2022">true</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2022To12_31_2022">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2022To12_31_2022">0000025743</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tmxd-20221231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="tmxd-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="tmxd-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="tmxd-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="tmxd-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P01_01_2022To12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_20_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-04-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit></ix:resources></ix:header></div><div><div style="background-color:white;display: inline;"><div style="text-align:center;text-indent: 0px;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto;text-indent: 0px;"><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div><div style="line-height: 3pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div><div style="margin-top: 4pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">UNITED STATES </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Washington, D.C. 20549 </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2022To12_31_2022">10-K/A</ix:nonNumeric></div></div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Amendment No.&#160;1) </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></td></tr></table><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">For the fiscal year ended <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P01_01_2022To12_31_2022" format="ixt:date-monthname-day-year-en"><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P01_01_2022To12_31_2022" format="ixt:date-monthname-day-en">December 31</ix:nonNumeric>, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2022To12_31_2022">2022</ix:nonNumeric></ix:nonNumeric></div> </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">or </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></td></tr></table><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">For the transition period from<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> to<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div> </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Commission File Number: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P01_01_2022To12_31_2022">001-00100</ix:nonNumeric></div></div> </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g497484g0427043027505.jpg"/> </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 24pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2022To12_31_2022">THERAPEUTICSMD, INC.</ix:nonNumeric></div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Exact name of Registrant as specified in its Charter) </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td style="width:48%">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:stateprovnameen">Nevada</ix:nonNumeric></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2022To12_31_2022">87-0233535</ix:nonNumeric></div></div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(State or other jurisdiction</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(I.R.S. Employer Identification No.)</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of incorporation or organization)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td style="width:48%">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2022To12_31_2022">951 Yamato Road</ix:nonNumeric></div>, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2022To12_31_2022">Suite 220</ix:nonNumeric></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2022To12_31_2022">Boca Raton</ix:nonNumeric></div>, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:stateprovnameen">Florida</ix:nonNumeric></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2022To12_31_2022">33431</ix:nonNumeric></div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Address of principal executive offices)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Zip Code)</div></div></td></tr></table><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2022To12_31_2022">561</ix:nonNumeric></div>-<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2022To12_31_2022">961-1900</ix:nonNumeric></div></div></div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Registrant&#8217;s telephone number, including area code) </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Act: </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="width:32%">&#160;</td>
<td style="vertical-align:bottom;width:1%">&#160;</td>
<td style="width:32%">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Title of Each Class</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Trading</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">symbol</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Name of each exchange on which registered</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2022To12_31_2022">Common Stock, par value $0.001 per share</ix:nonNumeric></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2022To12_31_2022">TXMD</ix:nonNumeric></div></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></div></div></div></td></tr></table><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(g) of the Act: None</div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<div style="display:inline;"><ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="P01_01_2022To12_31_2022">No</ix:nonNumeric></div>&#160;&#160; &#9746;</div></div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act. &#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744; &#160;&#160;&#160;&#160;<div style="display:inline;"><ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="P01_01_2022To12_31_2022">No</ix:nonNumeric></div>&#160;&#160;&#9746;</div></div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;<div style="display:inline;"><ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P01_01_2022To12_31_2022">Yes</ix:nonNumeric></div>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</div></div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="display:inline;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;&#160;&#160;<div style="display:inline;"><ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P01_01_2022To12_31_2022">Yes</ix:nonNumeric></div>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="display:inline;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>of the Exchange Act:</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 816px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 163.188px;"></td>
<td style="vertical-align: bottom; width: 8.15625px;"></td>
<td style="width: 448.812px;"></td>
<td style="vertical-align: bottom; width: 8.15625px;"></td>
<td style="width: 163.188px;"></td>
<td style="vertical-align: bottom; width: 8.15625px;"></td>
<td style="width: 16.3438px;"></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: bottom;"><div style="display:inline;">Large&#160;Accelerated&#160;Filer</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#9744;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">Accelerated&#160;filer</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#9744;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="display:inline;"></div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: bottom;"><div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#9746;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">Smaller&#160;reporting&#160;company</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"><div style="display:inline;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="display:inline;"></div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: bottom;"><div style="display:inline;">Emerging&#160;growth&#160;company</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"><div style="display:inline;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</div></div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#160;&#160;<div style="display:inline;"><ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div></div></div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If&#160;securities are&#160;registered pursuant to&#160;Section 12(b)&#160;of&#160;the&#160;Act,&#160;indicate by&#160;check&#160;mark&#160;whether the&#160;financial statements of&#160;the&#160;registrant included in&#160;the&#160;filing&#160;reflect&#160;the&#160;correction of&#160;an&#160;error&#160;to&#160;previously issued financial statements.&#160;&#160;&#160;&#9744;</div></div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="display:inline;">Indicate by&#160;check&#160;mark&#160;whether any&#160;of&#160;those&#160;error&#160;corrections&#160;are&#160;restatements&#160;that&#160;required a&#160;recovery&#160;analysis of&#160;incentive-based compensation received by&#160;any&#160;of&#160;the&#160;registrant&#8217;s&#160;executive officers during the&#160;relevant recovery period pursuant<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to&#160;&#167;240.10D-1(b).&#160;&#160;&#160;&#9744;</div></div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="display:inline;">Indicate by check mark whether the registrant is a shell company (as defined in Rule<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>of the Exchange Act). &#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;<div style="display:inline;"><ix:nonNumeric name="dei:EntityShellCompany" contextRef="P01_01_2022To12_31_2022" format="ixt:fixed-false">&#9746;</ix:nonNumeric></div></div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="display:inline;">As of June&#160;30, 2022, the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the voting and<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>common equity held by<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>computed by reference to the market price at which the common equity was last sold was $<div style="display:inline;"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">87,323,238</ix:nonFraction></div>.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April&#160;20, 2023, there were outstanding <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn04_20_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,135,323</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.001 per share. </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 816px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 285.594px;"></td>
<td style="vertical-align: bottom; width: 8.15625px;"></td>
<td style="width: 261.109px;"></td>
<td style="vertical-align: bottom; width: 8.15625px;"></td>
<td style="width: 252.984px;"></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;"><div style="display:inline;">Auditor Firm Id: (PCAOB ID Number <div style="display:inline;"><ix:nonNumeric name="dei:AuditorFirmId" contextRef="P01_01_2022To12_31_2022">248</ix:nonNumeric></div>)</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">Auditor Name: <div style="display:inline;"><ix:nonNumeric name="dei:AuditorName" contextRef="P01_01_2022To12_31_2022">GRANT THORNTON LLP</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">Auditor Location: <div style="display:inline;"><ix:nonNumeric name="dei:AuditorLocation" contextRef="P01_01_2022To12_31_2022">Miami, Florida</ix:nonNumeric></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 1em; margin-bottom: 0em; break-before: page;"></div></div></div><hr style="color:#999999;height:3px;width:100%"/><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">EXPLANATORY NOTE </div></div><ix:nonNumeric name="dei:AmendmentDescription" contextRef="P01_01_2022To12_31_2022"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment No.&#160;1 on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A,</div> or the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A,</div> is being filed by TherapeuticsMD, Inc., or the Company, in order to disclose information required by Items 10, 11, 12, 13 and 14 of Part III of Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> which information was omitted from the Company&#8217;s Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the fiscal year ended December&#160;31, 2022, or the Original Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> in reliance on Instruction G to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> The Original Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> was filed with the Securities and Exchange Commission, or SEC, on April&#160;7, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not expect to file its definitive proxy statement for its upcoming annual stockholders&#8217; meeting within 120 days of the end of its most recent fiscal year (as required under Instruction G to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K).</div> Therefore, the Company is filing this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A</div> in order to include information that would have been contained in the definitive proxy statement into the Original Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> The Company is also filing as exhibits to this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A</div> new certifications with respect to this filing by its principal executive officer and principal financial officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002; accordingly, Item 15 of Part IV has also been amended to reflect the filing of these new exhibits. Because no financial statements are being filed in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A,</div> and this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A</div> does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K,</div> paragraphs 3, 4 and 5 of the certifications have been omitted. The Company is also not filing new certifications required under Section&#160;906 of the Sarbanes-Oxley Act of 2002, since no financial statements are being filed with this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A.</div> Finally, the Company is filing this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A</div> to delete the reference on the cover of the Original Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> to the incorporation by reference of portions of its definitive proxy statement into Part III of the Original Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A</div> is limited in scope to the items identified above and should be read in conjunction with the Original Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> and the Company&#8217;s other filings with the SEC. This Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A</div> does not reflect events occurring after the filing of the Original Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> or modify or update those disclosures affected by subsequent events. Consequently, all other information is unchanged and reflects the disclosures made at the time of the filing of the Original Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Part III </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:6%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:88%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Page</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;10.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx497484_1">Directors, Executive Officers and Corporate Governance</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;11.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx497484_2">Executive Compensation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;12.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx497484_3">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;13.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx497484_4">Certain Relationships and Related Transactions, and Director Independence</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;14.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx497484_5">Principal Accountant Fees and Services</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Part IV </span></p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:6%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:90%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;15.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx497484_6">Exhibits and Financial Statement Schedules</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx497484_7">Signatures</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART III </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx497484_1">Item&#160;10. Directors, Executive Officers and Corporate Governance </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding the current directors of the Company. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:48%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:44%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy G. Thompson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">80</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chairman of the Board&#160;<sup style="font-size:75%; vertical-align:top">(2)</sup></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cooper C. Collins</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">43</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director&#160;<sup style="font-size:75%; vertical-align:top">(1)(2)</sup></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gail K. Naughton, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">67</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director&#160;<sup style="font-size:75%; vertical-align:top">(1)</sup></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Justin Roberts</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">40</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director&#160;<sup style="font-size:75%; vertical-align:top">(1)(2)</sup></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the Compensation Committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the Audit Committee. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:75%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">TOMMY&#160;G.&#160;THOMPSON</span> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Chairman of the Board</p> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Director Since:</span> 2012</p> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Age:</span> 80</p> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Committee:</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Audit</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Biographical Information</p> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tommy G. Thompson served as the Chairman of the Board of Directors and a director of our company from May&#160;2012 until he was appointed as Executive Chairman of the Board of Directors on September&#160;6, 2022. From July 2020 until March 2022, Secretary Thompson served as the Interim President of the University of Wisconsin system. Secretary Thompson also serves as the Chief Executive Officer of Thompson Holdings, a consulting firm. As the Governor of Wisconsin from January 1987 to February 2001, Secretary Thompson was perhaps best known for his efforts to revitalize the Wisconsin economy, for his national leadership on welfare reform, and for his work toward expanding healthcare access across all segments of society. As the former Secretary of the U.S.&#160;Department of Health&#160;&amp; Human Services, or HHS, from February 2001 to January 2005, Secretary Thompson served as the nation&#8217;s leading advocate for the health and welfare of all Americans. Secretary Thompson was a partner in the law firm of Akin Gump Strauss Hauer&#160;&amp; Feld LLP, or Akin Gump, from March 2005 to January 2012, when he resigned to run for the United States Senate. Secretary Thompson served as an Independent Chairman of the Deloitte Center for Health Solutions, a healthcare consulting company, from March&#160;2005 to May 2009. At the Deloitte Center for Health Solutions and at Akin Gump, Secretary Thompson built on his efforts at HHS to work toward developing solutions to the healthcare challenges facing American families, businesses, communities, states, and the nation as a whole. Secretary Thompson has also served as the President of Logistics Health, Inc., a provider of medical readiness and homeland security solutions, from February 2005 to January 2011. Secretary Thompson has served as a Senior Fellow for the Bipartisan Policy Center, a <span style="white-space:nowrap">non-profit</span> organization focused on bipartisan advocacy and policymaking, since July 2013. Secretary Thompson also serves as a member of the board of directors for United Therapeutics Corporation [NASDAQ: UTHR] and Physicians Realty Trust [NYSE: DOC]. Secretary Thompson also served as a member of the boards of directors of Tyme Technologies, Inc. [NASDAQ: TYMI] from August 2017 to February 2020, C. R. Bard, Inc. [NYSE: BCR] from August 2005 to January 2018 and Centene Corporation [NYSE: CNC] from April 2005 to January 2022, and has historically served on the boards of directors of other public companies.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Key Qualifications and Experience</p> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">We believe Secretary Thompson&#8217;s experience in public service and on the boards of directors of numerous public companies, particularly his services and knowledge related to the healthcare industry as a whole, makes him well suited to serve on our Board of Directors. Secretary Thompson received both his B.S.&#160;and J.D. from the University of Wisconsin-Madison.</p></td></tr>
</table> <p style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td style="width:75%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">COOPER&#160;C.&#160;COLLINS</span> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Director&#160;Since:</span>&#160;2012</p> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Age:</span> 43</p> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Committees:</p> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Audit</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Compensation</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Biographical Information</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooper C. Collins has served as a director of our company since February 2012. Mr.&#160;Collins has served as Chief Executive Officer of Fortis BioPharma LLC since June 2015. Mr.&#160;Collins served as Chief Strategy Officer of Pernix Therapeutics Holdings, Inc. [NASDAQ: PTX], or Pernix, from May 2013 until April 2014, as its President and Chief Executive Officer from March&#160;2010 until May 2013, and as a director from March 2010 until February 2014. Mr.&#160;Collins joined Pernix Therapeutics, Inc., a predecessor of Pernix, in 2002, where he was appointed as a director in January 2007, its President in December 2007 and its Chief Executive Officer in June 2008, serving in those three capacities until March 2010. From December 2005 to December 2007, Mr.&#160;Collins served as Vice President of Business and Product Development of Pernix Therapeutics, Inc. and as its Territory Manager from December 2003 to December 2005. Mr.&#160;Collins was employed for three years by the National Football League franchise, the New Orleans Saints, in its media relations department.</p> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Key Qualifications and Experience</p> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">We believe Mr.&#160;Collins&#8217; specialty pharmaceutical company knowledge and executive experience provide the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors. While on a football scholarship, Mr.&#160;Collins received a B.A. from Nicholls State University, where he later received an M.B.A.</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td style="width:75%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">GAIL&#160;K.&#160;NAUGHTON,<br />PH.D. </span> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Director&#160;Since:</span>&#160;2020</p> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Age:</span> 67</p> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Committee:</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Compensation</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Biographical Information</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gail K. Naughton, Ph.D. has served as a director of our company since March 2020. Dr.&#160;Naughton has served as the Chief Scientific Officer and Chief Business Development Officer of Histogen, a company she founded which is focused on the development of novel solutions based on the products of cells grown under simulated embryonic conditions, since April 2017. Dr.&#160;Naughton served as the Chairman and Chief Executive Officer of Histogen from June 2007 until April 2017. Prior to Histogen, Dr.&#160;Naughton was the Vice Chairman of Advanced Tissue Sciences, Inc., a human-based tissue engineering company, from March 2002 to October 2002, President from August 2000 to March 2002, President and Chief Operating Officer from 1995 to 2000 and&#160;Executive Vice President, Chief Operating Officer from 1991 to 1995. Dr.&#160;Naughton also served as Dean of the College of Business Administration at San Diego State University from August 2002 to June 2011.&#160;She has spent over 30 years extensively researching the tissue engineering process, holds over 105 U.S. and foreign patents, and has founded two regenerative medicine companies. Dr.&#160;Naughton has brought several tissue engineered products to market including a product for severe burns (TransCyte), a dermal replacement for diabetic ulcers (Dermagraft), an aesthetic dermal filler (Cosmederm/Cosmeplast), and SkinMedica&#8217;s TNS product for skin care. Dr.&#160;Naughton has been extensively published and a frequent speaker in the field of tissue engineering. In 2000, Dr.&#160;Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering. Dr.&#160;Naughton also serves as a member of the board of directors for CEL-SCI Corporation [NYSE American: CVM] and previously served as a member of several public company boards of directors since 1988, including Cytori Therapeutics, Inc. [NASDAQ: CYTX] from July 2014 until January 2018.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Key Qualifications and Experience</p> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">We believe Dr.&#160;Naughton&#8217;s extensive executive experience, her <span style="white-space:nowrap">in-depth</span> knowledge of the healthcare industry and regenerative medicine technology, her experience developing <span style="white-space:nowrap">FDA-approved</span> products, and her service on other public company boards and committees, provide the requisite qualifications, skills, perspectives, and experience that make her well qualified to serve on our Board of Directors. Dr.&#160;Naughton received her B.S. in Biology from St. Francis College, her M.S. in Histology and her Ph.D. in Hematology from the New York University Medical Center and her E.M.B.A. from UCLA.</p></td></tr>
</table> <p style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:9%"></td>
<td style="width:75%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-family:Times New Roman"><span style="font-weight:bold">JUSTIN&#160;ROBERTS</span></span> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Director&#160;Since:</span>&#160;2022</p> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Age:</span> 40</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Committees:</p> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Audit</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Compensation</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Biographical Information</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Roberts is a Partner at Rubric Capital Management LP, a role he has held since the formation of the company in 2016. He currently serves as a <span style="white-space:nowrap">Non-Executive</span> Director of Mereo BioPharma [NASDAQ: MREO]. Before Rubric he spent seven years at Point72 Asset Management. Mr.&#160;Roberts has also held roles at ZS Associates, Moore Capital Management, and began his career at Lehman Brothers as an investment banker in their M&amp;A practice.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Key Qualifications and Experience</p> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">We believe Mr.&#160;Roberts&#8217; extensive executive experience, his finance background, and his service on other public company boards and committees, provide the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors. Mr.&#160;Roberts graduated with honors from Johns Hopkins University.</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding our current executive officers: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:48%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:44%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marlan D. Walker</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">48</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Executive Officer</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Company&#8217;s transformation into a pharmaceutical royalty company, the termination of our executive management team (except for Mr.&#160;Marlan Walker, our former General Counsel and current Chief Executive Officer) and all other employees was completed by December&#160;31, 2022. Listed below are biographical descriptions of our current executive officer and our principal financial and accounting officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Marlan Walker</span> has served as Chief Executive Officer of our company since December 2022. Previously he served as General Counsel of our company from March 2016. Mr.&#160;Walker previously also served as Chief Development Officer from April 2018 to December 2019 and as our Corporate and Intellectual Property Counsel from June 2013 until he became our General Counsel. Mr.&#160;Walker&#8217;s experience is focused in management of legal issues and risk in the life science industries across a variety of disciplines. His legal practice prior to his time at TherapeuticsMD included long-term portfolio strategy and management, patent preparation and prosecution, contract negotiation and drafting, life-cycle management, and Hatch-Waxman matters. After law school, he took a position at Greenberg Traurig, LLP in August 2005. In March of 2009, he moved to Luce Forward Hamilton&#160;&amp; Scripps. Mr.&#160;Walker accepted an <span style="white-space:nowrap">in-house</span> position as Intellectual Property Counsel for Medicis Pharmaceutical Corp. in June 2011, which was acquired by Valeant Pharmaceutical International, Inc. in December 2012. In February 2013, Mr.&#160;Walker accepted a position at Kilpatrick Townsend&#160;&amp; Stockton, but chose to move <span style="white-space:nowrap">in-house</span> again in June 2013, when he accepted a position at our company. Mr.&#160;Walker graduated from Arizona State University Sandra Day O&#8217;Connor College of Law with his J.D. in 2004, and an LL.M. in Intellectual Property Law at The George Washington University Law School in 2005. He holds a Master&#8217;s Degree in Molecular Biology and a B.S. degree, both earned from Brigham Young University<span style="font-style:italic">.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Michael C. Donegan</span> served as Interim Chief Financial Officer of our Company from April&#160;2022, Chief Accounting Officer of our Company from November 2020 and Vice President Finance of our Company from April 2013. Mr.&#160;Donegan ceased serving in these roles effective as of December&#160;30, 2022, however he is continuing to serve as the Company&#8217;s Principal Financial Officer and Principal Accounting Officer in a consulting capacity. Mr.&#160;Donegan has a 30-year background in accounting and finance. From August 2012 to April 2013, Mr.&#160;Donegan served as an independent consultant exclusively for our Company, where he conceptualized, designed and executed our Sarbanes-Oxley 404 compliance program. From August 2007 to August 2012, Mr.&#160;Donegan served as an independent consultant designing and implementing Sarbanes-Oxley 404 compliance programs for various non-accelerated filers and executed on pre-designed Sarbanes-Oxley 404 compliance programs for certain large accelerated filers. From January 2005 to August 2007, Mr.&#160;Donegan served as an independent consultant exclusively for Tyco International, where he enhanced and executed the Sarbanes-Oxley 404 compliance model with their corporate headquarters group. From November 2001 to December 2004, Mr.&#160;Donegan was Manager of Financial Systems at Tyco International at its global headquarters. From 1994 to 2001, Mr.&#160;Donegan held various positions in the global consolidation/SEC reporting group at Sensormatic Electronics Corporation culminating with the acquisition of Sensormatic Electronics Corporation by Tyco International in the fall of 2001 when he was the Manager of Financial Systems. Mr.&#160;Donegan began his career at Ernst&#160;&amp; Young, LLP where he worked in both the audit and tax departments. Mr.&#160;Donegan earned his B.S. in Accounting and his Master of Accounting from the University of Florida. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">CORPORATE GOVERNANCE </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since October&#160;9, 2017, our common stock has been listed on the Nasdaq Global Select Market of the Nasdaq Stock Market LLC, or Nasdaq, under the symbol &#8220;TXMD.&#8221; From April&#160;23, 2013 to October&#160;6, 2017, our common stock was listed on the NYSE American under the symbol &#8220;TXMD.&#8221; Under the rules of Nasdaq, independent directors must comprise a majority of a listed company&#8217;s board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors has affirmatively determined, after considering all the relevant facts and circumstances, that each of Dr.&#160;Gail Naughton, and Messrs. Tommy G. Thompson, Cooper C. Collins and Justin Roberts is an independent director, and that Ms.&#160;Karen&#160;L. Ling and Messrs. Paul M. Bisaro, Jules A. Musing and Angus C. Russell were independent directors prior to their resignations in December 2022, as &#8220;independence&#8221; is defined under the applicable rules and regulations of the SEC and the listing standards of Nasdaq, and does not have a relationship with us (either directly or as a partner, stockholder, or officer of an organization that has a relationship with us) that would interfere with their exercise of independent judgment in carrying out their responsibilities as directors. Accordingly, a majority of our directors are independent, as required under the applicable Nasdaq rules. Mr.&#160;Hugh O&#8217;Dowd, our former Chief Executive Officer, was not considered an independent director prior to his resignation because of his executive position with our company. There are no family relationships among any of our directors or officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Committee Charters, Corporate Governance, and Code of Ethics </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors has adopted charters for the Audit and Compensation Committees describing the authority and responsibilities delegated to each committee by our Board of Directors. Our Board of Directors has also adopted Corporate Governance Guidelines, a Code of Conduct and Ethics, and a Code of Ethics for the Chief Executive Officer and senior financial officers of our company. We post on our website, at <span style="font-style:italic">www.therapeuticsmd.com</span>, the charters of our Audit and Compensation Committees; our Corporate Governance Guidelines, Code of Conduct and Ethics, and Code of Ethics for the Chief Executive Officer and senior financial officers, and any amendments or waivers thereto; and any other corporate governance materials contemplated by the SEC or Nasdaq. These documents are also available in print to any stockholder requesting a copy in writing from our corporate secretary at our executive offices. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Sessions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We regularly schedule executive sessions in which <span style="white-space:nowrap">non-employee</span> directors will meet without the presence or participation of management, with at least one of such sessions including only independent directors. Mr.&#160;Thompson, as the Executive Chairman of our Board of Directors, chairs the executive sessions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Committees </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors has an Audit Committee and a Compensation Committee, each consisting entirely of independent directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the relatively small size of our Board of Directors and the desire to involve the entire Board of Directors in nominating decisions, we have elected to no longer have a separate Nominating Committee. Since we do not have a Nominating Committee, our independent directors, who currently constitute all of the Board of Directors, determine the director nominees. Our Board of Directors may employ a variety of methods for identifying and evaluating director nominees. If vacancies are anticipated or arise, our Board of Directors considers various potential candidates who may come to our attention through current Board members, professional search firms, stockholders or other persons. These candidates may be evaluated by our Board of Directors at any time during the year. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In evaluating a director candidate, our Board of Directors will review their qualifications including capability, availability to serve, conflicts of interest, general understanding of business, understanding of our business and technology, educational and professional background, personal accomplishments and other relevant factors. Our Board of Directors has not established any specific qualification standards for director nominees, and we do not have a formal diversity policy relating to the identification and evaluation of nominees for director, although from time to time the Board of Directors may identify certain skills or attributes as being particularly desirable to help meet specific needs that have arisen. Our Board of Directors may also interview prospective nominees in person or by telephone. After completing this evaluation, the Board of Directors will determine the nominees. The Board has not adopted a formal process for considering director candidates who may be recommended by stockholders. However, our policy is to give due consideration to any and all such candidates. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:20%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:79%"></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">Audit Committee</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Members</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooper C. Collins, Chair</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Justin Roberts</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Tommy G. Thompson</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Audit Committee is to oversee our financial and reporting processes and the audits of our financial statements and to provide assistance to our Board of Directors with respect to its oversight of the integrity of our financial statements, our company&#8217;s compliance with legal and regulatory matters, the independent registered public accountant&#8217;s qualifications and independence, and the performance of our independent registered public accountant. The primary responsibilities of the Audit Committee are set forth in its charter and include various matters with respect to the oversight of our accounting and financial reporting process and audits of our financial statements on behalf of our Board of Directors. The Audit Committee also selects the independent registered public accountant to conduct the annual audit of our financial statements; reviews the proposed scope of such audit; reviews accounting and financial controls with the independent registered public accountant and our financial accounting staff; and reviews and approves any transactions between us and our directors, officers, and their affiliates.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Audit Committee currently consists of Messrs. Collins, Thompson and Roberts, each an independent director of our company under the listing standards of Nasdaq as well as under applicable rules and regulations of the SEC, with Mr.&#160;Collins serving as Chair. Mr.&#160;Russell served as the Chairman of the Audit Committee in 2021 and 2022 prior to his resignation from our Board of Directors in December 2022 and was an independent director of our company under the listing standards of Nasdaq as well as under applicable rules and regulations of the SEC. Our Board of Directors has determined that Mr.&#160;Thompson (whose background is detailed above) qualifies as an &#8220;audit committee financial expert&#8221;, and that Mr.&#160;Russell qualified as an &#8220;audit committee financial expert&#8221;, in accordance with applicable rules and regulations of the SEC.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt" colspan="3"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">Compensation Committee</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Members</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gail Naughton, Chair</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooper C. Collins</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Justin Roberts</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">The purpose of the Compensation Committee includes, among other things, determining, or recommending to our Board of Directors for determination, the compensation of our Chief Executive Officer and other executive officers and directors, and discharging the responsibilities of our Board of Directors relating to our compensation programs. Pursuant to its charter, the Compensation Committee may delegate any of its responsibilities to a subcommittee comprised of one or more members of the Compensation Committee. The Compensation Committee currently consists of Dr.&#160;Naughton and Messrs. Collins and Roberts, each an independent director of our company under the listing standards of Nasdaq as well as under applicable rules and regulations of the SEC, with Dr.&#160;Naughton serving as Chair. Ms.&#160;Ling and Mr.&#160;Musing each served as a member of the Compensation Committee, with Mr.&#160;Musing serving as Chair, until their resignations from our Board of Directors in December 2022, and each former member was an independent director of our company under the listing standards of Nasdaq as well as under applicable rules and regulations of the SEC.</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board&#8217;s Role in Risk Oversight </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Risk is inherent in every business. As is the case in virtually all businesses, we face a number of risks, including operational, economic, financial, legal, regulatory, and competitive risks. Our management is responsible for the <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> management of the risks we face. Our Board of Directors, as a whole and through its committees, has responsibility for the oversight of risk management. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors&#8217; involvement in our business strategy and strategic plans plays a key role in its oversight of risk management, its assessment of management&#8217;s risk appetite, and its determination of the appropriate level of enterprise risk. Our Board of Directors receives updates at least quarterly from senior management and periodically from outside advisors regarding the various risks we face, including operational, cybersecurity and information technology, economic, financial, legal, regulatory, and competitive risks. Our Board of Directors also reviews the various risks we identify in our filings with the SEC as well as risks relating to various specific developments, such as debt and equity issuances. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The committees of our Board of Directors assist our Board of Directors in fulfilling its oversight role in certain areas of risks. The Audit Committee oversees the financial and reporting processes of our company and the audit of the financial statements of our company and provides assistance to our Board of Directors with respect to the oversight and integrity of the financial statements of our company, our company&#8217;s compliance with legal and regulatory matters, the independent auditor&#8217;s qualification and independence, and the performance of our independent auditor. The Audit Committee also receives reports regarding our compliance program and our cybersecurity and information technology programs. The Compensation Committee considers the risks that our compensation policies and practices may have in attracting, retaining, and motivating valued employees and endeavors to assure that it is not reasonably likely that our compensation plans and policies would create undue risk or have a material adverse effect on our company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Diversity </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We seek diversity in experience, viewpoint, education, skill, and other individual qualities and attributes to be represented on our Board of Directors. We believe directors should have various qualifications, including individual character and integrity; business experience and leadership ability; strategic planning skills, ability, and experience; requisite knowledge of our industry and finance, accounting, and legal matters; communications and interpersonal skills; and the ability and willingness to devote time to our company. We also believe the skill sets, backgrounds, and qualifications of our directors, taken as a whole, should provide a significant mix of diversity in personal and professional experience, background, viewpoints, perspectives, knowledge, and abilities. Nominees are not to be discriminated against on the basis of race, religion, national origin, sex, sexual orientation, disability, or any other basis prohibited by law. The assessment of directors is made in the context of the perceived needs of our Board of Directors from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our directors have held high-level positions in business or professional service firms and have experience in dealing with complex issues. We believe that all of our directors are individuals of high character and integrity, are able to work well with others, and have committed to devote sufficient time to the business and affairs of our company. In addition to these attributes, the description of each director&#8217;s background sets forth above indicates the specific experience, qualifications, and skills necessary to conclude that each individual should continue to serve as a director of our company. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board Diversity Matrix set forth below reports self-identified diversity statistics for our Board of Directors in the format required by Nasdaq&#8217;s rules. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:69%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt" colspan="15"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" colspan="15" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:0.50em; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Board Diversity Matrix for TherapeuticsMD, Inc. (As of April 20, 2023)</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top" colspan="15"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Board size:</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total number of directors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">&#160;</td>
<td colspan="12" style="vertical-align:bottom;white-space:nowrap" align="center">4</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-family:Times New Roman"><span style="font-weight:bold">Gender:</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-family:Times New Roman">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-family:Times New Roman">Female</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-family:Times New Roman">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-family:Times New Roman">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-family:Times New Roman">Male</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-family:Times New Roman">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-family:Times New Roman">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-family:Times New Roman"><span style="white-space:nowrap">Non-Binary</span></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-family:Times New Roman">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-family:Times New Roman">Did&#160;not&#160;Disclose<br />Gender</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Directors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">1</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt" colspan="15"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top" colspan="15"><span style="font-weight:bold">Number of Directors who identify in any of the categories below:</span></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">African American or Black</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">0</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Alaskan Native or Native American</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">0</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Asian</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">0</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Hispanic or Latinx</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">0</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Native Hawaiian or Pacific Islander</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">0</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">White</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">0</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Two or More Races or Ethnicities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">0</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="14"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">LGBTQ+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">&#160;</td>
<td style="vertical-align:bottom" colspan="12" align="center">0</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="14"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Did Not Disclose Demographic Background</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">&#160;</td>
<td style="vertical-align:bottom" colspan="12" align="center">1</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Leadership Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that effective board leadership structure depends on the experience, skills, and personal interaction among persons in leadership roles as well as the needs of our company at any point in time. We currently maintain separate roles between the Chief Executive Officer and the Executive Chairman of the Board of Directors in recognition of the differences between the two responsibilities. Our Chief Executive Officer is responsible for setting our strategic direction and <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> leadership and performance of our company. The Executive Chairman of the Board of Directors provides input to the Chief Executive Officer, sets the agenda for board meetings, and presides over meetings of the full Board of Directors as well as executive sessions of our Board of Directors. Our Board of Directors believes that our current leadership structure provides the most effective leadership model for our company, as it promotes balance between the Board of Directors&#8217; independent authority to oversee our business and the Chief Executive Officer and his management team, which manage the business on a <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> basis. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Compensation Committee Interlocks and Insider Participation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During our fiscal years ended December&#160;31, 2021 and December&#160;31, 2022, Mr.&#160;Collins served as a member of the Compensation Committee. Ms.&#160;Ling and Mr.&#160;Musing served as members of the Compensation Committee until their resignations as members of the Board of Directors in December 2022 and Mr.&#160;Carroll served as a member of the Compensation Committee until his resignation as a member of the Board of Directors in December 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of Ms.&#160;Ling or Messrs. Collins or Musing have been at any time one of our officers or employees or had any relationship with us that requires disclosure under Item 404 of Regulation <span style="white-space:nowrap">S-K</span> under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal years ended December&#160;31, 2021 and December&#160;31, 2022, none of our executive officers served on the compensation committee or board of directors of any entity whose executive officers serve as a member of our Board of Directors or Compensation Committee. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Compensation Recovery Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2021, we adopted a general compensation recovery, or clawback, policy covering our annual and long-term incentive award plans and arrangements after the SEC adopts final rules implementing the requirement of Section&#160;954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the &#8220;Dodd-Frank Act&#8221;). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-Hedging and Anti-Pledging Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2020, the Board of Directors amended the Company&#8217;s Code of Conduct and Ethics to include a policy regarding hedging and pledging transactions. Pursuant to the policy, directors, officers, and employees are prohibited from: (1)&#160;directly or indirectly engaging in any hedging transactions with respect to any directly or indirectly owned securities of the company, which includes the purchase of any financial instrument (including puts, calls, equity swaps, forward contracts, collars, exchange funds or other derivative securities) on an exchange or in any other market in order to hedge or offset any decrease in the market value of such securities; (2)&#160;engaging in short sale transactions or forward sale transactions or any short-term or speculative transactions in the company&#8217;s securities or in other transactions in the company&#8217;s securities that may lead to inadvertent violations of insider trading laws; and (3)&#160;pledging securities of the company as collateral for a loan or otherwise using securities of the company to secure a debt, including through the use of traditional margin accounts with a broker. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board and Committee Meetings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors held a total of 37 meetings during the fiscal year ended December&#160;31, 2022. No director attended fewer than 75% of the aggregate of (i)&#160;the total number of meetings of our Board of Directors and (ii)&#160;the total number of meetings held by all committees of our Board of Directors on which such director was a member. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal year ended December&#160;31, 2022, the Audit Committee held six meetings, the Compensation Committee held nine meetings and the Nominating and Corporate Governance Committee held two meetings. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Annual Meeting Attendance </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We encourage our directors to attend each annual meeting of stockholders. All of our directors virtually attended the 2021 annual meeting of stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Communications with Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders may communicate with our Board of Directors or specific members of our Board of Directors, including our independent directors and the members of our various board committees, by submitting a letter addressed to our Board of Directors of TherapeuticsMD, Inc. at the address set forth in this annual report c/o any specified individual director or directors. Any such letters are forwarded to the indicated directors. In addition, at the request of the Board of Directors, communications that do not directly relate to our Board of Directors&#8217; duties and responsibilities as directors will be excluded from distribution. Such excluded items include, among others, &#8220;spam,&#8221; advertisements, mass mailings, form letters, and email campaigns that involve unduly large numbers of similar communications; solicitations for goods, services, employment or contributions; and surveys. Additionally, communications that appear to be unduly hostile, intimidating, threatening, illegal or similarly inappropriate will also be screened for omission. Any excluded communication will be made available to any director upon his or her request. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx497484_2">Item&#160;11. Executive Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a smaller reporting company, the rules of the U.S. Securities and Exchange Commission permit us to omit the Compensation Discussion and Analysis section and to report the compensation of our principal executive officer, each of our two other most highly compensated executive officers who were serving as executive officers on December 31, 2022, our former principal executive officer, and two additional former executive officers for whom disclosure would have been provided but for the fact that the individual was not serving as an executive officer on December 31, 2022 (collectively, our NEOs). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For 2022, our NEOs were: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Marlan Walker, CEO </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Brian Bernick, Former Interim co-CEO </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Mark Glickman, Former Interim co-CEO </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Hugh O&#8217;Dowd, Former CEO </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">James D&#8217;Arecca, Former CFO </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Michael Donegan, Former Interim CFO </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 6, 2022, Mr. Hugh O&#8217;Dowd ceased serving as Chief Executive Officer of our Company and Dr. Bernick and Mr. Glickman were appointed as Interim Co-Chief Executive Officers. On December 30, 2022, Dr. Bernick and Mr. Glickman ceased serving as Interim Co-Chief Executive Officers of our Company and Mr. Walker was appointed Chief Executive Officer. Mr. Donegan ceased serving as Interim Chief Financial Officer effective as of December 30, 2022, however he is continuing to serve as the Company&#8217;s Principal Financial Officer and Principal Accounting Officer in a consulting capacity. In connection with the Company&#8217;s transformation into a pharmaceutical royalty company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief Executive Officer) and all other employees was completed by December 31, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Fiscal Year 2022 Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table lists the compensation of our NEOs for the years provided. The following information includes the dollar value of salaries, bonus awards, the number of awards granted, <span style="white-space:nowrap">non-equity</span> incentive plan compensation, and certain other compensation, if any. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:50%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Principal &#160;&#160;Position</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Bonus<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock<br />Awards<sup style="font-size:75%; vertical-align:top">(1)</sup><br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Awards<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Non-Equity<br />Incentive Plan<br />Compensation<sup style="font-size:75%; vertical-align:top">(2)</sup><br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other<br />Compensation<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top" rowspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Marlan D. Walker<sup style="font-size:75%; vertical-align:top">(3)</sup></p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Chief Executive Officer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">424,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">207,500</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">292,656</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">466,875</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,224</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(6)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,417,755</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">415,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,090,987</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,806</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(6)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,597,193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top" rowspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Michael Donegan<sup style="font-size:75%; vertical-align:top">(3)</sup></p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Former Interim Chief Financial Officer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">307,308</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">90,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">135,072</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(7)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">295,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,860</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(8)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">846,740</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top" rowspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Brian Bernick, M.D.<sup style="font-size:75%; vertical-align:top">(3)</sup></p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Former Interim Co-Chief Executive Officer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">292,656</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(9)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">812,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,860</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(10)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,624,016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top" rowspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Mark Glickman<sup style="font-size:75%; vertical-align:top">(3)</sup></p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Former Interim Co-Chief Executive Officer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">408,462</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">175,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">292,656</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(11)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">608,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">118,860</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(12)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,428,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top" rowspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Hugh O&#8217;Dowd<sup style="font-size:75%; vertical-align:top">(3)</sup></p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Former Chief Executive Officer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">521,442</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,391,900</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(14)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">725,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,966</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(15)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,664,308</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">273,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(13)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,372,500</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(14)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">289,495</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(15)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,934,995</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top" rowspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">James C. D&#8217;Arecca<sup style="font-size:75%; vertical-align:top">(3)</sup></p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Former Chief Financial Officer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">121,731</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">86,160</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(17)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">207,890</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">420,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,048,669</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(16)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">126,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">126,985</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(17)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,721,654</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the grant date fair value of restricted stock units (RSUs) and performance restricted stock units (PSUs) granted. The number of PSUs represents the maximum number of PSUs that may vest. The actual number of PSUs that will vest will depend on the Company&#8217;s achievement of certain performance goals. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts in this column represent the amounts earned and payable under our annual performance-targeted incentive plan, which were earned and payable during the indicated fiscal year but were not paid until after the end of indicated fiscal year. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">On April&#160;1, 2022, Mr.&#160;D&#8217;Arecca ceased serving as the Chief Financial Officer and Principal Financial Officer of the Company. On September&#160;6, 2022, Mr.&#160;O&#8217;Dowd ceased serving as the Company&#8217;s Chief Executive Officer. On December&#160;30, 2022, Mr.&#160;Bernick and Mr.&#160;Glickman ceased serving as the Company&#8217;s Interim Co-Chief Executive Officers. Effective December 30, 2022, Mr.&#160;Donegan ceased serving as the Chief Financial Officer of the Company and Mr.&#160;Walker was appointed as the Chief Executive Officer of the Company. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts represent retention bonuses paid in 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For 2022, the amount represents (i)&#160;5,200 PSUs with a grant date fair value of $179,400 and (ii)&#160;5,200 RSUs with a grant date fair value of $113,256. For 2021, the amount represents (i)&#160;231,130 RSUs with a grant date fair value of $252,051, which includes 57,797 RSUs with a grant date fair value of $42,318 awarded in connection to the 2021 Stock Option Exchange Program, and (ii)&#160;693,336 PSUs with a grant date fair value of $838,936 assuming maximum payout. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For 2022, other compensation paid was related to (i)&#160;employer match to 401(k) plan of $2,000, and (ii)&#160;health and welfare benefits paid by the Company. For 2021, other compensation paid was related to (i)&#160;employer match to 401(k) plan of $2,000, and (ii)&#160;health and welfare benefits paid by the Company. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For 2022, the amount represents (i)&#160;2,400 PSUs with a grant date fair value of $82,800 and (ii)&#160;4,200 RSUs with a grant date fair value of $52,272. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For 2022, other compensation paid was related to (i)&#160;employer match to 401(k) plan of $2,000, and (ii)&#160;health and welfare benefits paid by the Company. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For 2022, the amount represents (i)&#160;5,200 PSUs with a grant date fair value of $179,400 and (ii)&#160;5,200 RSUs with a grant date fair value of $113,256. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For 2022, other compensation paid was related to (i)&#160;employer match to 401(k) plan of $2,000, and (ii)&#160;health and welfare benefits paid by the Company. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For 2022, the amount represents (i)&#160;5,200 PSUs with a grant date fair value of $179,400 and (ii)&#160;5,200 RSUs with a grant date fair value of $113,256. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For 2022, other compensation paid includes (i)&#160;$100,000 for consulting fees paid pursuant to Mr.&#160;Glickman&#8217;s agreement, (ii)&#160;employer match to 401(k) plan of $2,000, and (iii)&#160;health and welfare benefits paid by the Company. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For 2021, the amount represents a sign-on bonus paid to Mr.&#160;O&#8217;Dowd. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(14)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For 2022, the amount represents (i)&#160;42,500 PSUs with a grant date fair value of $1,466,250 and (ii)&#160;42,500 RSUs with a grant date fair value of $925,650. For 2021, the amount represents 550,000 RSUs with a grant date fair value of $2,186,250 and 550,000 PSUs with a grant date fair value of $2,186,250. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(15)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For 2022, other compensation paid includes (i)&#160;$11,321 for unused vacation, (ii)&#160;employer match to 401(k) plan of $2,000, and (iii)&#160;health and welfare benefits paid by the company. For 2021, other compensation paid was related to (i)&#160;reimbursed taxable relocation expenses of $282,293, (ii)&#160;employer match to 401(k) plan of $2,000, and (iii)&#160;health and welfare benefits paid by the Company. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(16)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For 2021, the amount represents (i)&#160;3,467 RSUs with a grant date fair value of $209,733 and (ii)&#160;13,867 PSUs with a grant date fair value of $838,936 assuming maximum payout. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(17)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For 2022, other compensation paid includes (i)&#160;$43,270 for unused vacation, (ii)&#160;$32,815 of travel reimbursement, (iii)&#160;employer match to 401(k) plan of $2,000, and (iv)&#160;health and welfare benefits paid by the company. For 2021, other compensation paid was related to (i)&#160;reimbursed taxable travel expenses of $102,179 reflecting travel to and from the Company&#8217;s headquarters in Florida, (ii)&#160;employer match to 401(k) plan of $2,000, and (iii)&#160;health and welfare benefits paid by the Company. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx256418_40">Outstanding Equity Awards at Fiscal <span style="white-space:nowrap">Year-End</span> 2022 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to outstanding equity-based awards held by our NEOs at December&#160;31, 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option Awards</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Equity</span><br /><span style="font-weight:bold">Award<br />Date</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of&#160;Securities<br />Underlying&#160;Unexercised&#160;Options</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Exercise&#160;Price<br />($)</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option</span><br /><span style="font-weight:bold">Expiration&#160;Date</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Exercisable<br />(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Unexercisable<br />(#)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Marlan D. Walker</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">06/21/2013</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">149.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">06/21/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/03/2013</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">157.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/03/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">06/05/2014</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">201.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">06/05/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11/21/2014</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11/21/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">07/30/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">109.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">07/30/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Michael Donegan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">06/21/2013</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">149.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">06/21/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">08/28/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">136.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">08/28/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Brian Bernick</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">08/28/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(1)&#160;</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">136.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/30/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This amount reflects fully vested stock options for which Mr.&#160;Bernick had 90 days to exercise following his separation. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:49%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="22" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock Awards</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number</span><br /><span style="font-weight:bold">of&#160;Shares<br />or Units of<br />Stock<br />That&#160;Have<br />Vested&#160;and<br />Not Yet<br />Settled<br />(#)</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Market</span><br /><span style="font-weight:bold">Value</span><br /><span style="font-weight:bold">of&#160;Shares<br />or Units of<br />Stock<br />That&#160;Have<br />Vested&#160;and<br />Not Yet<br />Settled<sup style="font-size:75%; vertical-align:top">(1)</sup><br />($)</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Equity Incentive</span><br /><span style="font-weight:bold">Plan Awards</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Equity<br />Award<br />Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number<br />of Shares<br />or Units<br />of Stock<br />That&#160;Have<br />Not<br />Vested</span><br /><span style="font-weight:bold">(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Market</span><br /><span style="font-weight:bold">Value of<br />Shares or<br />Units of<br />Stock<br />That&#160;Have<br />Not<br />Vested<sup style="font-size:75%; vertical-align:top">(2)</sup></span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number<br />of&#160;Shares<br />or Units<br />of Stock<br />That&#160;Have<br />Not<br />Vested (#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Market</span><br /><span style="font-weight:bold">Value of<br />Shares or<br />Units of<br />Stock<br />That&#160;Have<br />Not<br />Vested<sup style="font-size:75%; vertical-align:top">(4)</sup></span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Marlan D. Walker</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/30/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,010</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,646</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,030</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,938</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">07/01/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,311</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,918</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,467</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,379</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">09/29/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">770</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/23/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,200</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/31/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,200</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(6)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Michael Donegan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/30/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,497</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">07/01/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,466</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">09/29/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">519</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,901</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/23/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,416<br /></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/31/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,416</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Mark Glickman</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/15/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,366</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">85,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/23/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/31/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Brian Bernick, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/20/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,584</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">07/01/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">09/29/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/23/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/31/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Hugh O&#8217;Dowd</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">08/31/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">204,963</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/23/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">237,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/31/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">237,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:43%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td>
<td style="height:3.75pt" colspan="4"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">James C. D&#8217;Arecca</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amount reflects vested RSUs that were settled in January 2023. The amounts in this column are based on the closing price of our common stock on December&#160;30, 2022 of $5.59. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts in this column are based on the closing price of our common stock on December&#160;30, 2022 of $5.59. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amount reflects RSUs that vest&#160;one-third&#160;annually beginning on the equity award date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amount reflects the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number depending on the Company&#8217;s achievement of break-even quarterly EBITDA. The performance measurement period is between the second quarter 2020 and the fourth quarter 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amount reflects the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number depending on the Company&#8217;s achievement of certain (i)&#160;revenue goals for 2023 or (ii)&#160;revenue CAGR targets from 2021 to 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amount reflects the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number, depending on the total shareholder return milestone achieved. The performance measurement period is from April 1, 2022 to March 31, 2025. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Post-Employment Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pension Benefits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not offer any defined benefit pension plans for any of our employees. We have a 401(k) plan in which employees may participate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our executive officers are eligible to participate in our employee benefit plans, including medical and dental plans. These plans are available to all employees and do not discriminate in favor of executive officers. It is generally our policy to not extend significant perquisites to executives that are not broadly available to our other employees. In designing these elements, we seek to provide an overall level of benefits that is competitive with that offered by similarly situated companies in the markets in which we operate based upon our general understanding of industry practice. These benefits are not considered in determining the compensation of our executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employment Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marlan D. Walker has an amended and restated employment agreement, as amended (the &#8220;Walker Employment Agreement&#8221;), with the Company that commenced on December&#160;18, 2018, and was amended twice effective October&#160;15, 2021 and December&#160;30, 2022. The Walker Employment Agreement provides that we will continue to employ Mr.&#160;Walker, and Mr.&#160;Walker will continue to serve the Company, unless sooner terminated pursuant to the terms of the Walker Employment Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Walker Employment Agreement provides for: (i)&#160;a base salary of $428,000 per year until April&#160;15, 2023; thereafter, a base salary of $500,000 per year and a <span style="white-space:nowrap">lump-sum</span> bonus payment of $20,909, (ii)&#160;an annual short-term incentive compensation of 50% of salary, at the discretion of our Board of Directors, and (iii)&#160;70,000 RSUs vesting on June&#160;30, 2023. Mr.&#160;Walker will receive employee benefits, vacation, and other perquisites as may be determined from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conditions of termination call for (i)&#160;termination immediately upon death, (ii)&#160;termination upon a disability in which Mr.&#160;Walker is unable to perform his duties for more than six consecutive months, (iii)&#160;voluntary termination without good reason by Mr.&#160;Walker with prior notice, (iv)&#160;involuntary termination by our Company without good cause, (v)&#160;termination for good cause, and (vi)&#160;termination for good reason wherein Mr.&#160;Walker will have 90 days from the date of occurrence of a condition giving rise to good reason to provide a notice of termination of his employment with the Company, which will be effective 31 days after we receive notice and the criteria remains uncorrected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Potential Payments Upon Termination or Change in Control </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have employment agreements with certain of our executive officers as described above. The arrangements reflected in these employment agreements are designed to encourage the officers&#8217; full attention and dedication to our Company currently and, in the event of any proposed change in control, provide these officers with individual financial security. The employment agreements provide for specified payments and benefits by us to our executive officers only upon a qualifying termination of employment as described below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective April&#160;1, 2022, Mr.&#160;James&#160;C. D&#8217;Arecca transitioned from his position as the Company&#8217;s Chief Financial Officer; his termination was by the Executive without Good Reason, as that term was defined in his Employment Agreement. Effective September&#160;6, 2022, Mr.&#160;O&#8217;Dowd transitioned from his position as the Company&#8217;s Chief Executive Officer; his termination was by the Company without Good Cause, as that term was defined in his Employment Agreement. Effective December&#160;30, 2022, Dr.&#160;Bernick transitioned from his position as the Company&#8217;s Co-Chief Executive Officer; his termination was by the Company without Good Cause, as that term was defined in his Amended and Restated Employment Agreement. Effective December&#160;30, 2022, Mr.&#160;Glickman transitioned from his position as the Company&#8217;s Co-Chief Executive Officer; his termination was by the Company without Good Cause, as that term was defined in his Employment Agreement. Effective December&#160;30, 2022, Mr.&#160;Donegan transitioned from his position as the Company&#8217;s Interim Chief Financial Officer; his termination was by the Company without Good Cause, as that term was defined in his Amended and Restated Employment Agreement. The Company entered into a Consulting Agreement with Mr.&#160;Donegan, pursuant to which Mr.&#160;Donegan will continue to serve as the Company&#8217;s Principal Financial and Accounting Officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise set forth below, the terminations of Messrs. D&#8217;Arecca, O&#8217;Dowd, Glickman, and Donegan, and Dr.&#160;Bernick (together, the &#8220;Departed Officers&#8221;), and the severance and other termination benefits paid to each of them was in accordance with their respective Employment Agreements or Amended and Restated Employment Agreement, as applicable, and no discretionary severance amounts were paid. Information with respect to the Employment Agreement and Amended and Restated Employment Agreement, as applicable, for each Departed Officer, is provided for each of his actual terms of separation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Termination by Us Without Good Cause or by Executive with Good Reason &#8212; No Change in Control </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Mr.&#160;O&#8217;Dowd&#8217;s Employment Agreement, he is entitled to receive (i)&#160;an amount equal to his annual base salary, which was provided in a single lump sum, (ii)&#160;an amount equal to his targeted annual bonus award for 2022, which amount was provided in a single lump sum, (iii)&#160;COBRA benefits for a period of eighteen (18)&#160;months following his termination, (iv)&#160;all unvested equity compensation, including performance-based equity at target level achievement, held by the executive will vest as of the effective date of such termination, and (v)&#160;payment for accrued but unused paid time off consistent with the Company&#8217;s policies and procedures therefor in effect. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Dr.&#160;Bernick&#8217;s Amended and Restated Employment Agreement, Mr.&#160;Glickman&#8217;s Employment Agreement, and Mr.&#160;Donegan&#8217;s Amended and Restated Employment Agreement, Dr.&#160;Bernick, Mr.&#160;Glickman, and Mr.&#160;Donegan are each entitled to receive (i)&#160;the executive&#8217;s annual base salary for a period of twelve (12)&#160;months following the effective date of such termination, (ii)&#160;an amount equal to the executive&#8217;s targeted annual bonus award for 2022, (iii) COBRA benefits for a period of twenty-four (24)&#160;months following the executive&#8217;s termination, (iv)&#160;all unvested equity compensation, including performance-based equity at target level achievement, held by the executive will vest as of the effective date of such termination, and (v)&#160;payment for accrued but unused paid time off consistent with the Company&#8217;s policies and procedures therefor in effect (the &#8220;Separation Benefits&#8221;). Mr.&#160;Glickman also received $100,000 for ongoing consulting services. In addition to the amount received for ongoing consulting services and the Separation Benefits, Mr.&#160;Glickman received the fourth tranche of his performance bonus ($131,250) awarded under the 2022 Executive Retention and Performance Bonus Plan (the &#8220;ERB Plan&#8221;) and the second tranche of his performance bonus ($131,250) awarded under the ERB Plan, in exchange for providing transition assistance to the Company through March&#160;31, 2023. In addition to the Separation Benefits, Mr.&#160;Donegan received the fourth tranche of his performance bonus ($67,500) awarded under the ERB Plan and the second tranche of his performance bonus ($67,500) awarded under the&#160;ERB Plan,&#160;in exchange for providing transition assistance to the Company through March&#160;31, 2023, to be paid in a single lump sum within thirty (30)&#160;days following the end of the transition period. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with his termination without Good Cause effective as of December 30, 2022, the Company entered into a General Consulting and Services Agreement with MCD Consulting and Management Services, LLC (&#8220;MCD&#8221;), the manager of which is Mr.&#160;Donegan (the &#8220;Consulting Agreement&#8221;). Pursuant to the Consulting Agreement, Mr.&#160;Donegan provides consulting services deemed to be the functional equivalent of services normally and customarily provided by an employed chief financial officer until such time as Mr.&#160;Donegan transitions his role to a third party provider. The Consulting Agreement will be in effect until the completion of Mr.&#160;Donegan&#8217;s services. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Consulting Agreement, MCD received a signing fee of $100,000 and will receive an additional fee of $50,000 per month. In addition, because the term of the Consulting Agreement was extended past March&#160;31, 2023, MCD will receive an hourly fee of $205.28 per hour of services performed by Mr.&#160;Donegan. Because the Consulting Agreement was not terminated by MCD prior to March&#160;31, 2023, or by the Company due to MCD&#8217;s material breach prior to March&#160;31, 2023, MCD received an <span style="white-space:nowrap">additional&#160;one-time&#160;fee</span> of $100,000 on March&#160;31, 2023. In addition, Mr.&#160;Donegan&#160;received a grant of 50,000 RSUs that vested on March&#160;31, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Walker Employment Agreement, for Mr.&#160;Walker, in the event of termination of the executive&#8217;s employment without &#8220;cause&#8221; (referred to as &#8220;good cause&#8221; in the Walker Employment Agreement) or resignation by the executive for &#8220;good reason&#8221; (as each term is defined in the Walker Employment Agreement), he would be entitled to, subject to his signing and not revoking a full and complete release of all claims against the Company and its affiliates, (i)&#160;the sum of his salary, payable on a biweekly basis ratably over eighteen (18)&#160;months, and one and one half times (1.5x) his target annual incentive compensation for the fiscal year in which such termination of employment occurs, (ii)&#160;a continuation of welfare benefits for a period of two years after such termination, (iii)&#160;COBRA benefits for a period of twenty-four (24)&#160;months following such termination, (iv)&#160;payment for any annual short-term incentive compensation earned for the calendar year immediately preceding the calendar year of such termination, (v)&#160;unpaid accrued base salary and unused vacation pay through the termination date, and (vi)&#160;amounts accrued but unpaid at the time of termination. Furthermore, the above obligations of the Company are subject to the executive complying with a <span style="white-space:nowrap">non-solicitation</span> agreement of employees and customers, and a <span style="white-space:nowrap">non-competition</span> agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Termination or Resignation in Connection with a Change in Control </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of termination of Mr. Walker&#8217;s employment without &#8220;good cause&#8221; or resignation by the executive for &#8220;good reason&#8221; in the 12 months following a change in control, Mr.&#160;Walker would have all the benefits and obligations for termination without a change in control, except that he would receive the sum of his salary and continuation of welfare benefits for 18 months and would receive 150% of his targeted annual bonus award. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Termination by Reason of Death or Disability </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Mr.&#160;Walker, in the event of termination of the executive&#8217;s employment by reason of his death or &#8220;disability&#8221; (as such term is defined in the Walker Employment Agreement), in addition to those payments and benefits provided to salaried employees generally, including amounts accrued but unpaid at the time of termination, he would be entitled to <span style="white-space:nowrap">(i)&#160;pro-rated</span> target annual incentive compensation for the fiscal year in which such termination of employment occurs, payable in a lump sum, subject to the executive&#8217;s signing and not revoking a full and complete release of all claims against the company and its affiliates in the event of a disability, (ii)&#160;immediate vesting of all outstanding equity awards that vest solely on the passage of time, (iii)&#160;accrued but unused vacation pay through the termination date, payable in a lump sum, and (iv)&#160;all other rights and benefits the executive is vested in, pursuant to other plans and programs of our company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Termination by the Executive Without Good Reason </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Mr.&#160;D&#8217;Arecca&#8217;s Employment Agreement, he is entitled to receive no further compensation under his Employment Agreement other than the payment of his base salary that accrued and remained unpaid as of the date of his termination, unreimbursed business expenses, and accrued but unused paid time off consistent with the Company&#8217;s policies and procedures therefor in effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below reflects the amount of compensation to Marlan Walker, the only NEO currently employed by the Company, assuming termination of such executive&#8217;s employment without cause or for good reason or following a change in control of our company on December&#160;31, 2022. Other than as set forth below, no amounts will be paid to our NEOs in the event of termination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Marlan Walker </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:59%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Executive Benefits and Payments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Termination<br />Without Good<br />Cause<br />or&#160;with&#160;Good<br />Reason&#160;(Not&#160;in<br />Connection&#160;with<br />a&#160;Change<br />in&#160;Control)<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Termination<br />Without<br />Good Cause<br />or&#160;with<br />Good&#160;Reason<br />Following<br />a&#160;Change<br />in&#160;Control<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Termination&#160;by<br />Reason&#160;of<br />Death or<br />Disability</span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash severance</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,125,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(1)&#160;</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,125,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity awards<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">127,014</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">127,014</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">127,014</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of payments due to executive for (i)&#160;18 months of his then current salary, (ii)&#160;150% target annual incentive compensation, (iii)&#160;health and welfare benefits for 24 months, (iv)&#160;unsued PTO, and (v)&#160;any annual short-term incentive compensation earned from the prior year that had not yet been paid by the Company. Mr.&#160;Walker&#8217;s salary was increased from $428,000 to $500,000 effective April&#160;15, 2023. Amounts above reflect (i)&#160;18 months of his then current salary and (ii)&#160;150% target annual incentive compensation. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of payments due to executive for (i)&#160;18 months of his then current salary, (ii)&#160;150% target annual incentive compensation, (iii)&#160;unsued PTO, and (iv)&#160;any annual short-term incentive compensation earned from the prior year that had not yet been paid by the Company. Mr.&#160;Walker&#8217;s salary was increased from $428,000 to $500,000 effective April&#160;15, 2023. Amounts above reflect (i)&#160;18 months of his then current salary and (ii)&#160;150% target annual incentive compensation. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents full annual incentive compensation that would be prorated based on termination date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the value of unvested equity awards that would become fully vested. The value is calculated by multiplying the number of shares underlying each accelerated award by the difference between $5.59, the per share closing price of the common stock on December&#160;30, 2022, and the per share exercise price, if any. If the exercise price was below $5.59, no value was attributable to the accelerated vesting of the awards. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Nonqualified Defined Contribution and Nonqualified Deferred Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not offer any nonqualified defined contribution plans or nonqualified deferred compensation plans for any of our NEOs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Limitation of Directors&#8217; Liability; Indemnification of Directors, Officers, Employees, and Agents </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Amended and Restated Articles of Incorporation and bylaws, each as amended, provide that we may indemnify to the full extent of our power to do so, all directors, officers, employees, and/or agents. The effect of this provision in the Amended and Restated Articles of Incorporation, as amended, is to eliminate the rights of our company and our stockholders, either directly or through stockholders&#8217; derivative suits brought on behalf of our company, to recover monetary damages from a director for breach of the fiduciary duty of care as a director except in those instances described under Nevada law. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification by our company for liabilities arising under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), may be permitted to officers and directors of our company pursuant to the foregoing provisions or otherwise, we are aware that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">DIRECTOR COMPENSATION </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We compensate our <span style="white-space:nowrap">non-employee</span> directors with a combination of cash and equity. Our Board of Directors receives the following cash compensation for their service: each director receives an annual cash retainer of $57,500; the chairperson of the Board receives an additional $22,500 annual cash retainer; the chairperson of our Audit Committee receives an annual cash retainer of $30,000 and the other members of the Audit Committee receive an annual cash retainer of $15,000; the chairperson of the Compensation Committee receives an annual cash retainer of $20,000 and the other members of the Compensation Committee receive an annual cash retainer of $12,000; and the chairperson of each of our other committees receives an annual cash retainer of $12,500 and the other members receive an annual cash retainer of $7,500. We also reimburse our directors for reasonable expenses related to attendance at Board of Directors and committee meetings. In addition, each director who served on our Board of Directors after September&#160;29, 2022 received an annual award of 5,000 restricted stock units, with the exception of the Chairman of the Board who received an annual award of 34,175 restricted stock units. All restricted stock units granted to our directors in 2022 represent a contingent right to receive one share of common stock and will vest on the one year anniversary of the date of grant. We do not pay our directors per meeting fees. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table and accompanying footnotes detail compensation paid to our directors for services rendered for the year ended December&#160;31, 2022. Mr.&#160;Roberts is entitled to receive compensation in the same manner as our other <span style="white-space:nowrap">non-employee</span> directors, but he has elected not to receive any compensation for his service as a <span style="white-space:nowrap">non-employee</span> director at this time. Mr.&#160;O&#8217;Dowd&#8217;s compensation is described above under &#8220;Executive Compensation.&#8221; </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:59%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name<sup style="font-size:75%; vertical-align:top">(1)</sup> </p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fees&#160;Earned<br />or&#160;Paid&#160;in&#160;Cash<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock<br />Awards<sup style="font-size:75%; vertical-align:top">(2)</sup><br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other<br />Compensation<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Tommy G. Thompson<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">229,998</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">379,998</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Paul M. Bisaro<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">90,868</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">124,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cooper C. Collins</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">92,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">125,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Karen L. Ling<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">76,456</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">110,106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Jules A. Musing<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70,544</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104,194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Gail Naughton, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">72,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">106,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Angus C. Russell<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">87,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">121,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Justin Roberts<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Robert G. Finizio<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,507</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,507</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As of December 31, 2022, each of the directors listed in the &#8220;Director Compensation&#8221; table had the following awards outstanding: </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:82%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Awards<br />(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock<br />Awards<br />(#)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Tommy G. Thompson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Paul M. Bisaro</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cooper C. Collins</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Karen L. Ling</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Jules A. Musing</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Gail Naughton, Ph.D. </p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Angus C. Russell</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Justin Roberts</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Robert G. Finizio</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">We grant RSUs for shares of common stock to non-employee directors. We value our RSUs by reference to our stock price on the date of grant. We recognize compensation expense for RSUs based on a straight-line basis over the requisite service period of the entire award. For further information, see &#8220;Note 10 &#8211; Stockholders&#8217; deficit&#8221; of the financial statements included in our most recent Annual Report on Form 10-K. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">These individuals resigned from the Board of Directors on December 30, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr. Finizio resigned from the Board of Directors on February 17, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr. Roberts joined the Board of Directors on August 23, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr. Thompson was appointed Executive Chairman of the Board of Directors on September 6, 2022. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx497484_3">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">SECURITY OWNERSHIP OF PRINCIPAL STOCKHOLDERS, DIRECTORS, AND OFFICERS </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of our common stock as of April&#160;20, 2023, by the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our directors and named executive officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of our directors and executive officers as a group; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he, she, or it possesses sole or shared voting or investment power of that security, including options and warrants that are currently exercisable or exercisable within 60 days of April&#160;20, 2023. Shares issuable pursuant to stock options, warrants, and convertible securities are deemed outstanding for computing the percentage of the person holding such options, warrants, or convertible securities but are not deemed outstanding for computing the percentage of any other person. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons named in the table below have sole voting and investment power with respect to all shares of common stock shown that they beneficially own, subject to community property laws where applicable. The information does not necessarily indicate beneficial ownership for any other purpose. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o TherapeuticsMD, Inc., 951 Yamato Road, Suite 220, Boca Raton, Florida 33431. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:77%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares&#160;Beneficially&#160;Owned</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of Beneficial Owners</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percent<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers and Directors:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marlan D. Walker<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy G. Thompson<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cooper C. Collins<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">56,622</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gail K. Naughton, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Justin Roberts</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Bernick, MD<sup style="font-size:75%; vertical-align:top">(5)(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James D&#8217;Arecca<sup style="font-size:75%; vertical-align:top">(6)</sup><sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,476</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Donegan<sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65,753</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark A. Glickman<sup style="font-size:75%; vertical-align:top">(6)(9)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hugh O&#8217;Dowd<sup style="font-size:75%; vertical-align:top">(6)(10)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">121,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executives and directors as a group (5&#160;persons)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">124,416</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">5% Stockholders:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rubric Capital Management LP<sup style="font-size:75%; vertical-align:top">(11)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,757,191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents less than 1% of the outstanding shares of our common stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on 10,135,323 shares outstanding as of April&#160;20, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes (i) 12,307 shares held by Mr. Walker directly, and (ii)&#160;14,800 shares issuable to Mr. Walker upon the exercise of vested stock options. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes (i)&#160;14,312 shares held by Thompson Family Investments, LLC, an entity solely owned by Thompson Family Holdings, LLC, an entity solely owned by Mr.&#160;Thompson, (ii)&#160;5,954 shares held by Mr.&#160;Thompson directly, (iii)&#160;21 shares held indirectly by Thompson Family Holdings, LLC and (iv)&#160;20,400 shares issuable to Mr.&#160;Thompson upon the exercise of vested stock options. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes (i)&#160;46,722 shares held by Mr. Collins directly and (ii)&#160;9,900 shares issuable to Mr.&#160;Collins upon the exercise of vested stock options. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes (i) 29,819 shares held by Mr.&#160;Bernick directly, (ii)&#160;35,147 shares held by BF&#160;Investment Enterprises Ltd. (&#8220;BF Investment&#8221;) and (iii)&#160;60 shares held by BF&#160;Management, LLC (the &#8220;GP&#8221;), the general partner of BF&#160;Investment. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
Mr.&#160;Bernick (i)&#160;holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in the GP, (ii)&#160;holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii)&#160;holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv)&#160;serves as the Manager of the GP. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Messrs.&#160;Bernick, Glickman, O&#8217;Dowd, and D&#8217;Arecca left the Company in 2022. Accordingly, the Company does not have beneficial ownership information for these individuals as of April&#160;20, 2023. The information above is based on SEC filings and records of the Company. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 2,476 shares held by Mr. D&#8217;Arecca directly. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes (i)&#160;61,853 shares held by Mr.&#160;Donegan directly and (ii)&#160;3,900 shares issuable to Mr.&#160;Donegan upon the exercise of vested stock options. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 27,060 shares held by Mr. Glickman directly. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 121,666 shares held by Mr. O&#8217;Dowd directly. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based solely on the Form 4 filed with the SEC by Rubric Capital Management LP on December 12, 2022. The address of Rubric Capital Management LP is 155 East 44th Street, Suite&#160;1630, New York, NY 10017. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">EQUITY COMPENSATION PLAN INFORMATION </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the following table shows the number of securities to be issued upon exercise of outstanding options under equity compensation plans approved by our stockholders, which plans do not provide for the issuance of warrants or other rights. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:57%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">&#160;&#160;&#160;&#160;<br />&#160;&#160;&#160;&#160;<br />&#160;&#160;&#160;&#160;<br />&#160;&#160;&#160;&#160;<br />&#160;&#160;&#160;&#160;<br />&#160;&#160;&#160;&#160;<br />(a)<br />Number of Securities to be Issued Upon</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">(b)</span><br /><span style="font-weight:bold">Weighted-<br />Average<br />Exercise<br />Price of<br />Outstanding<br />Options<br />($)</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">(c)<br />Number of<br />Securities<br />Remaining<br />Available For<br />Future<br />Issuance<br />Under Equity</span><br /><span style="font-weight:bold">Compensation<br />Plans<br />(Excluding<br />Securities<br />Reflected in<br />Columns&#160;(a))<sup style="font-size:75%; vertical-align:top">(2)</sup><br />(#)</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Plan Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Exercise of<br />Outstanding<br />Options<br />(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Vesting and<br />Settlement&#160;of<br />Restricted<br />Stock Units<br />(&#8220;RSUs&#8221;)<br />(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Vesting and<br />Settlement&#160;of<br />Performance<br />Stock Units<br />(&#8220;PSUs&#8221;)<sup style="font-size:75%; vertical-align:top">(1)</sup><br />(#)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity Compensation Plans Approved by Stockholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019 Plan<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">115,676</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99,812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">122.89</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">352,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2012 Plan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,808</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">281.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2009 Plan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">114,478</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">266.97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity Compensation Plans Not Approved by Stockholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">None</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This number includes 80,573 PSUs that vested as of December&#160;31, 2022 and settled in January 2023. The actual number of PSUs that will vest will be between zero and 19,239 depending on the Company&#8217;s achievement of certain performance goals. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The number of remaining shares of common stock available for future issuance is based on an assumption that the maximum performance goals for PSUs were achieved, where applicable. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx497484_4">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Policy Relating to Related Party Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a policy that we will not enter into any material transaction in which a director or officer has a direct or indirect financial interest unless the transaction is determined by our Board of Directors to be fair to us or is approved by a majority of our disinterested directors or by our stockholders, as provided for under Nevada law. Generally, our Board of Directors as a whole, other than an affected director, if applicable, determines whether a director or officer has a direct or indirect (<span style="font-style:italic">i.e.</span>, any) financial interest in a transaction deemed material based upon our Code of Conduct and Ethics and Nevada law. From time to time, our Audit Committee, in accordance with its charter, will also review potential conflict of interest transactions involving members of our Board of Directors and our executive officers. The policy with respect to such transactions is provided in our company&#8217;s Code of Conduct and Ethics. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Related Party Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than compensation arrangements, we describe below transactions and series of similar transactions, since January&#160;1, 2021, to which we were a party or will be a party, in which: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amounts involved exceeded or will exceed $120,000; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any of our directors, executive officers, or holders of more than 5% of our voting securities, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compensation arrangements for our directors and NEOs are described elsewhere in this annual report. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Agreements with Catalent, Inc. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2015, J. Martin Carroll, a former director of our company, was appointed to the board of directors of Catalent, Inc. Mr.&#160;Carroll resigned from our board of directors effective December&#160;31, 2021. From time to time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. These agreements, however, were transferred to Mayne Pharma as part of our transaction with Mayne. Since July 2015, agreements with Catalent were reviewed by independent directors of our company, or a committee consisting of independent directors of our company during the time in which Mr.&#160;Carroll sat on our board of directors. During the years ended December&#160;31, 2022, 2021 and 2020, we were billed by Catalent approximately $4,287,181, $4,839,531, and $5,007,040, respectively, for manufacturing activities related to our clinical trials, <span style="white-space:nowrap">scale-up,</span> registration batches, stability, and validation testing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Agreements with American International Group, Inc. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2020, Karen L. Ling was appointed to our Board of Directors. At the time, Ms. Ling served as Executive Vice President and Chief Human Resources Officer of American International Group, Inc., or AIG. Ms.&#160;Ling resigned from our Board of Directors effective December&#160;30, 2022. From time to time, we have entered into agreements with AIG in the normal course of business. Agreements with AIG have been reviewed by independent directors of our Company, or a committee consisting of independent directors of our Company, since April 2020. During the years ended December&#160;31, 2022, 2021 and 2020, we were billed by AIG approximately $10,000, $43,000, and $187,000 for various insurance coverage for our company. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Agreements with Rubric Capital Management LP </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;23, 2022, we appointed Mr.&#160;Justin Roberts as a director to fill a newly created vacancy on the Board of Directors. As a director of the Company, Mr.&#160;Roberts is entitled to receive compensation in the same manner as our other <span style="white-space:nowrap">non-employee</span> directors, but he has elected not to receive any compensation for his service as a <span style="white-space:nowrap">non-employee</span> director at this time. Mr.&#160;Roberts currently serves as a Partner of Rubric. On July&#160;29, 2022, September&#160;30, 2022, October&#160;28, 2022 and May 1, 2023, we entered into subscription agreements with Rubric. On December&#160;30, 2022, and in accordance with the terms of the Certificate of Designation, the Company redeemed all 29,000 outstanding shares of the Company&#8217;s Series A Preferred Stock from Rubric at a purchase price of $1,333 per share. The Company also paid certain affiliates of Rubric approximately $3.0&#160;million as a make-whole payment pursuant to the subscription agreements previously entered into between the Company and Rubric. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See <span style="font-style:italic">Item 10 &#8211; Directors, Executive Officers and Corporate Governance</span> above for a discussion on director independence. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx497484_5">Item&#160;14. Principal Accountant Fees and Services </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate fees billed to our company for the fiscal year ended December&#160;31, 2022 and 2021 by Grant Thornton, our independent registered public accounting firm, were as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:80%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">&#160;&#160;&#160;&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">560,923</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">539,829</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-related fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">242,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104,146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">868,224</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">649,365</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Audit fees consist of fees associated with the annual audit, the reviews of our annual and quarterly reports, and other filings with the SEC as well as comfort letters and consents. Audit-Related Fees consist of fees for the audit of the financial statements of our former subsidiary vitaCare Prescription Services, Inc. Tax fees included the preparation of our tax returns and other related services. All Other Fees consist of fees associated with consulting and advisory services. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Audit Committee <span style="white-space:nowrap">Pre-Approval</span> Policies and Procedures </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The charter of our Audit Committee provides that the duties and responsibilities of our Audit Committee include the <span style="white-space:nowrap">pre-approval,</span> or adopting procedures for <span style="white-space:nowrap">pre-approval,</span> of all audit, audit-related, tax, and other services permitted by law or applicable SEC regulations (including fee and cost ranges) to be performed by our independent auditor. Any <span style="white-space:nowrap">pre-approved</span> services that will involve fees or costs exceeding <span style="white-space:nowrap">pre-approved</span> levels will also require specific <span style="white-space:nowrap">pre-approval</span> by the Audit Committee. Unless otherwise specified by the Audit Committee in <span style="white-space:nowrap">pre-approving</span> a service, the <span style="white-space:nowrap">pre-approval</span> will be effective for the <span style="white-space:nowrap">12-month</span> period following <span style="white-space:nowrap">pre-approval.</span> The Audit Committee will not approve any <span style="white-space:nowrap">non-audit</span> services prohibited by applicable SEC regulations or any services in connection with a transaction initially recommended by the independent auditor, the purpose of which may be tax avoidance and the tax treatment of which may not be supported by the Internal Revenue Code and related regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent deemed appropriate, the Audit Committee may delegate <span style="white-space:nowrap">pre-approval</span> authority to the Chairperson of the Audit Committee or any one or more other members of the Audit Committee provided that any member of the Audit Committee who has exercised any such delegation must report any such <span style="white-space:nowrap">pre-approval</span> decision to the Audit Committee at its next scheduled meeting. The Audit Committee will not delegate to management the <span style="white-space:nowrap">pre-approval</span> of services to be performed by the independent auditor. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Audit Committee requires that our independent auditor, in conjunction with our Chief Financial Officer, be responsible for seeking <span style="white-space:nowrap">pre-approval</span> for providing services to us and that any request for <span style="white-space:nowrap">pre-approval</span> must inform the Audit Committee about each service to be provided and must provide detail as to the particular service to be provided. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the services provided by Grant Thornton described above were approved by our Audit Committee pursuant to our Audit Committee&#8217;s <span style="white-space:nowrap">pre-approval</span> policies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART IV </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx497484_6">Item&#160;15. Exhibits and Financial Statement Schedules </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left"><span style="font-weight:bold">(a)</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial statements and financial statements schedules </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) All financial statements are omitted for the reason that they are not required, or the information is otherwise supplied in Item 8. &#8220;Financial Statements and Supplementary Data&#8221; in the Original Form 10-K. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) No financial statement schedules are included because such schedules are not applicable, are not required, or because required information is included in the consolidated financial statements or notes thereto contained in the Original Form 10-K. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left"><span style="font-weight:bold">(b)</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Exhibits </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:95%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap">Exhibit<br />No.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;2.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000101968709002459/croff_8k-ex0201.htm">Agreement and Plan of Reorganization, dated July&#160;6, 2009, among Croff Enterprises, Inc., AMHN Acquisition Corp., America&#8217;s Minority Health Network, Inc., and the Major Shareholders(1)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;2.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510138955/dex101.htm">Agreement and Plan of Reorganization, dated June&#160;11, 2010, among AMHN, Inc., SHN Acquisition Corp., Spectrum Health Network, Inc., and the Sole Shareholder of Spectrum Health Network, Inc.(2)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;2.3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000135601808000256/ex332.htm">Croff Enterprises, Inc. Plan of Corporate Division and Reorganization, dated October&#160;25, 2007(3)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;2.4</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111001316/ex-10_01.htm">Agreement and Plan of Merger, dated July&#160;18, 2011, among vitaMedMD, LLC, AMHN, Inc., and vitaMed Acquisition, LLC(4)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;2.5***+</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459022009476/txmd-ex21_221.htm">Stock Purchase Agreement, dated March&#160;6, 2022, by and between TherapeuticsMD, Inc. and GoodRx, Inc.(33)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;3.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex34.htm">Articles of Conversion of AMHN, Inc. filed in the State of Nevada, dated July&#160;20, 2010(5)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;3.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex35.htm">Articles of Incorporation of AMHN, Inc. filed in the State of Nevada, dated July&#160;20, 2010(5)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;3.3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex3-1.htm">Composite Amended and Restated Articles of Incorporation of the Company, as amended(35)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;3.4</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510149198/ddef14c.htm">Bylaws of the AMHN, Inc.(7)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;3.5</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex3-1.htm">First Amendment to Bylaws of the Company, dated December&#160;17, 2015(8)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;3.6</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459022022465/txmd-ex31_10.htm">Second Amendment to Bylaws of the Company, adopted May&#160;27, 2022(36)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;3.7</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522207645/d356180dex32.htm">Third Amendment to Bylaws of the Company, dated July&#160;29, 2022(37)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;3.8</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459022018687/txmd-ex31_8.htm">Certificate of Change to Articles of Incorporation of the Company(38)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;3.8</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522207645/d356180dex31.htm">Certificate of Designation, Preferences and Rights of Series A Preferred Stock (37)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;4.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113000166/ex4-2.htm">Form of Certificate of Common Stock(9)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;4.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Description of Securities of the Company<sup style="font-size:75%; vertical-align:top">(10)</sup></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002213/ex-10_3.htm">Form of Common Stock Purchase Warrant(11)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002213/ex-10_2.htm">Form of <span style="white-space:nowrap">Non-Qualified</span> Stock Option Agreement(11)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.3*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119004545/ex99-1.htm">TherapeuticsMD, Inc. 2019 Stock Incentive Plan(12)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.4*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312521116458/d152560ddef14a.htm">First Amendment to the TherapeuticsMD, Inc. 2019 Stock Incentive Plan(27)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.5*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113003145/ex10-34.htm">Amended and Restated 2012 Stock Incentive Plan(13)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.6*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312513399924/d611784dex991.htm">2009 Long Term Incentive Compensation Plan, as amended(14)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.7*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120004409/txmd-def14a_061820.htm">TherapeuticsMD, Inc. 2020 Employee Stock Purchase Plan(15)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.8</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713112000490/ex-10_3.htm">Form of Common Stock Purchase Warrant, dated February&#160;24, 2012(17)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.9</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113000292/ex10_1.htm">Common Stock Purchase Warrant, issued to Plato&#160;&amp; Associates, LLC, dated January&#160;31, 2013(18)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.10</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex4-1.htm">Form of Warrant to Purchase Common Stock, dated August&#160;5, 2020(6)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.11</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex4-2.htm">Amendment to Company Warrant issued by the Company to the Subscribers party to that certain Subscription Agreement, dated as of August&#160;5, 2020, dated November&#160;8, 2020(19)</a></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:94%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.12</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0000025743/000138713121003140/ex10-12.htm">Second Amendment to Company Warrant issued by the Company to the Subscribers party to that certain Subscription Agreement, dated as of August<span style="text-decoration:underline"></span>&#160;5, 2020(20)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.13</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0000025743/000138713121003140/ex10-13.htm">Warrant issued by the Company to Robert Finizio(20)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.14</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0000025743/000138713121003140/ex10-14.htm">Amendment to Warrant issued by the Company to Robert Finizio(20)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.15*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0000025743/000138713121003140/ex10-15.htm">Warrant issued by the Company to John C.K. Milligan, IV(20)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.16*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0000025743/000138713121003140/ex10-16.htm">Amendment to Warrant issued by the Company to John C.K. Milligan, IV(20)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.17</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-5.htm">Subscription Agreement, dated August<span style="text-decoration:underline"></span>&#160;5, 2020, by and among TherapeuticsMD, Inc. and the Subscribers identified on the Schedule of Subscribers attached thereto(6)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.18***</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713118005976/ex10-1.htm">License Agreement, dated July<span style="text-decoration:underline"></span>&#160;30, 2018, by and between TherapeuticsMD, Inc. and The Population Council, Inc.(22)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.19***</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119008469/ex10-2.htm">Lease, dated October<span style="text-decoration:underline"></span>&#160;5, 2018, by and between 951 Yamato Acquisition Company, LLC and TherapeuticsMD, Inc.(23)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.20*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459021042695/txmd-ex101_6.htm">Executive Employment Agreement, dated as of August<span style="text-decoration:underline"></span>&#160;3, 2021, by and between TherapeuticsMD, Inc. and Hugh O&#8217;Dowd(28)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.21*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459021046622/txmd-ex101_38.htm">TherapeuticsMD, Inc. Inducement Grant Restricted Stock Unit Agreement, dated as of August<span style="text-decoration:underline"></span>&#160;31, 2021, by and between TherapeuticsMD, Inc. and Hugh O&#8217;Dowd(29)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.22*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-6.htm">Employment Agreement, dated June<span style="text-decoration:underline"></span>&#160;1, 2020, between the Company and James C. D&#8217;Arecca(6)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.23*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459021056434/txmd-ex105_310.htm">Amendment to Employment Agreement, dated October<span style="text-decoration:underline"></span>&#160;15, 2021, between TherapeuticsMD, Inc. and James C. D&#8217;Arecca(30)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.24*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0000025743/000156459021050961/txmd-ex101_51.htm">Executive Employment Agreement, dated October<span style="text-decoration:underline"></span>&#160;15, 2021, by and between TherapeuticsMD, Inc. and Mark Glickman(31)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.25*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0000025743/000156459021050961/txmd-ex102_52.htm">TherapeuticsMD, Inc. Inducement Grant Restricted Stock Unit Agreement, dated October<span style="text-decoration:underline"></span>&#160;15, 2021, by and between TherapeuticsMD, Inc. and Mark Glickman(32)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.26*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex10-2.htm">Amended and Restated Employment Agreement, dated November<span style="text-decoration:underline"></span>&#160;24, 2020, between the Company and Michael Donegan(24)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.27*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120010302/ex10-1.htm">Amended and Restated Employment Agreement, dated November<span style="text-decoration:underline"></span>&#160;24, 2020, between the Company and Robert G. Finizio(24)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.28*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120010302/ex10-2.htm">Amended and Restated Employment Agreement, dated November<span style="text-decoration:underline"></span>&#160;24, 2020, between the Company and John C.K. Milligan, IV(24)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.29*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0000025743/000138713121004324/ex10-1.htm">Amendment, dated April<span style="text-decoration:underline"></span>&#160;8, 2021, to the Amended and Restated Employment Agreement, dated as of November<span style="text-decoration:underline"></span>&#160;24, 2020, by and between TherapeuticsMD, Inc. and John C.K. Milligan, IV(26)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.30*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0000025743/000138713121003140/ex10-41.htm">Employment Agreement, October<span style="text-decoration:underline"></span>&#160;30, 2019, between the Company and Edward J. Borkowski(20)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.31*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0000025743/000138713121003140/ex10-42.htm">Amendment to Employment Agreement between the Company and Edward J. Borkowski(20)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.32***</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119005935/ex10-3.htm">License and Supply Agreement, dated June<span style="text-decoration:underline"></span>&#160;6, 2019, by and between TherapeuticsMD, Inc. and Theramex HQ UK Limited(21)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.33*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex10-3.htm">Form of Indemnification Agreement between TherapeuticsMD, Inc. and each of its executive officers and directors(19)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.34</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120010302/ex1-1.htm">Controlled Equity OfferingSM Sales Agreement, dated November<span style="text-decoration:underline"></span>&#160;27, 2020, by and between TherapeuticsMD, Inc. and Cantor Fitzgerald<span style="text-decoration:underline"></span>&#160;&amp; Co.(24)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.35</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312521068004/d124843dex12.htm">Controlled Equity OfferingSM Sales Agreement, dated March<span style="text-decoration:underline"></span>&#160;3, 2021, by and between TherapeuticsMD, Inc. and Cantor Fitzgerald<span style="text-decoration:underline"></span>&#160;&amp; Co.(25)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.36*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459022011525/txmd-ex1055_277.htm">2022 Executive Retention and Performance Bonus Plan. <span style="white-space:nowrap">(ERB-Plan)(34)</span></a></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:95%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.37</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522207645/d356180dex101.htm">Subscription Agreement between TherapeuticsMD, Inc. and Rubric Capital Management LP, dated July&#160;29, 2022(37)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.38</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522207645/d356180dex102.htm">Subscription Agreement by and among TherapeuticsMD, Inc., Sixth Street Specialty Lending, Inc., TOP IV Talents, LLC and TOA Talents, LLC, dated July&#160;29, 2022(37)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.39</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522207645/d356180dex101.htm">Subscription Agreement between TherapeuticsMD, Inc. and Rubric Capital Management LP, dated September&#160;30, 2022(39)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.40</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522207645/d356180dex102.htm">Subscription Agreement by and among TherapeuticsMD, Inc., Sixth Street Specialty Lending, Inc., TOP IV Talents, LLC and TAO Talents, LLC, dated September&#160;30, 2022(39)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.41</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522273110/d394277dex101.htm">Subscription Agreement between TherapeuticsMD, Inc. and Rubric Capital Management LP, dated October&#160;28, 2022(40)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.42</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522273110/d394277dex102.htm">Subscription Agreement by and among TherapeuticsMD, Inc., Sixth Street Specialty Lending, Inc., TOP IV Talents, LLC and TAO Talents, LLC, dated October&#160;28, 2022(40)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.43***+</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522298002/d409080dex101.htm">License Agreement by and between TherapeuticsMD, Inc. and Mayne Pharma LLC, dated December&#160;4, 2022(41)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.44***+</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522298002/d409080dex102.htm">Transaction Agreement by and between TherapeuticsMD, Inc. and Mayne Pharma LLC, dated December&#160;4, 2022(41)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.45**</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex1045_158.htm">Amendment No.&#160;1 to the License Agreement between TherapeuticsMD, Inc. and Mayne Pharma LLC, dated as of December&#160;30, 2022(42) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.46</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex1046_159.htm">Amendment No.&#160;1 to the Transaction Agreement between TherapeuticsMD, Inc. and Mayne Pharma LLC, dated as of December&#160;30, 2022(42) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.47*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex1047_471.htm">Amended and Restated Employment Agreement, dated as of December&#160;18, 2018, by and between TherapeuticsMD, Inc. and Marlan Walker(42) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.48*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex1048_439.htm">Amendment, effective October&#160;15, 2021, to the Employment Agreement, dated as of December&#160;18, 2018, by and between TherapeuticsMD, Inc. and Marlan Walker </a>(42)</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.49*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312523050813/d372195dex101.htm">Amendment, dated February&#160;21, 2023, to the Employment Agreement, dated as of December&#160;18, 2018, as extended effective October&#160;15, 2021, by and between TherapeuticsMD, Inc. and Marlan Walker(16) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.50*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312523050813/d372195dex102.htm">General Consulting and Services Agreement by and between TherapeuticsMD, Inc. and MCD Consulting Management Services, LLC, dated February&#160;21, 2023(16) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">21.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex211_350.htm">Subsidiaries of the Company<sup style="font-size:75%; vertical-align:top">(42)</sup> </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex231_8.htm">Consent of Grant Thornton LLP<sup style="font-size:75%; vertical-align:top">(42)</sup> </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">31.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex311_7.htm">Certification of Chief Executive Officer pursuant to Rule <span style="white-space:nowrap">13a-14(a)</span> and Rule <span style="white-space:nowrap">15d-14(a)</span><sup style="font-size:75%; vertical-align:top"> (42)</sup> </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">31.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex312_10.htm">Certification of Chief Financial Officer pursuant to Rule <span style="white-space:nowrap">13a-14(a)</span> and Rule <span style="white-space:nowrap">15d-14(a)</span><sup style="font-size:75%; vertical-align:top"> (42)</sup> </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">31.3&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d497484dex313.htm">Certification of Chief Executive Officer pursuant to Rule <span style="white-space:nowrap">13a-14(a)</span> and Rule <span style="white-space:nowrap">15d-14(a)</span> </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">31.4&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d497484dex314.htm">Certification of Chief Financial Officer pursuant to Rule <span style="white-space:nowrap">13a-14(a)</span> and Rule <span style="white-space:nowrap">15d-14(a)</span> </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">32.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex321_6.htm">Section&#160;1350 Certification of Chief Executive Officer<sup style="font-size:75%; vertical-align:top">(42)</sup> </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">32.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex322_11.htm">Section&#160;1350 Certification of Chief Financial Officer<sup style="font-size:75%; vertical-align:top">(42)</sup> </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Inline XBRL for the cover page of this Annual Report on Form <span style="white-space:nowrap">10-K,</span> included in the Exhibit 101 Inline XBRL Document Set</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">* Indicates a contract with management or compensatory plan or arrangement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:95%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Certain confidential material contained in the document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been granted with respect to this omitted information.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">***</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(2). The omitted inform harm to the Company if publicly disclosed</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation <span style="white-space:nowrap">S-K.</span> The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed herewith.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8224;&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Furnished herewith.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(1)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on July&#160;10, 2009 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;000-16731).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(2)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on June&#160;14, 2010 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;000-16731).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(3)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2007 filed with the Commission on May&#160;1, 2008 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;000-16731).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(4)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on July&#160;21, 2011 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;000-16731).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(5)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">10-Q</span> for the quarter ended June&#160;30, 2010 filed with the Commission on August&#160;3, 2010 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;000-16731).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(6)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">10-Q</span> for the quarter ended June&#160;30, 2020 filed with the Commission on August&#160;7, 2020 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(7)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Definitive 14C Information Statement filed with the Commission on June&#160;29, 2010 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;000-16731).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(8)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on December&#160;22, 2015 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(9)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">S-3</span> filed with the Commission on January&#160;25, 2013 and incorporated hereby by reference (SEC File <span style="white-space:nowrap">No.&#160;333-186189).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(10)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2019 filed with the Commission on February&#160;24, 2020 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(11)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on October&#160;11, 2011 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;000-16731).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(12)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">S-8</span> filed with the Commission on June&#160;21, 2019 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;333-232268).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(13)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on August&#160;22, 2013 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(14)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Registration Statement on Form <span style="white-space:nowrap">S-8</span> filed with the Commission on October&#160;15, 2013 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;333-191730).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(15)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an appendix to the Definitive Proxy Statement filed with the Commission on May&#160;4, 2020 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(16)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on February&#160;27, 2023 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(17)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on February&#160;24, 2012 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;000-16731).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(18)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on February&#160;6, 2013 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;000-16731).</span></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:95%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(19)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">10-Q</span> filed with the Commission on November&#160;9, 2020 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(20)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2020 filed with the Commission on March&#160;4, 2021 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(21)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">10-Q</span> for the quarter ended June&#160;30, 2019 filed with the Commission on August&#160;9, 2019 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(22)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">10-Q</span> for the quarter ended September&#160;30, 2018 filed with the Commission on November&#160;8, 2018 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(23)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">10-Q</span> for the quarter ended September&#160;30, 2019 filed with the Commission on November&#160;8, 2019 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(24)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on November&#160;27, 2020 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(25)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Registration Statement on Form <span style="white-space:nowrap">S-3</span> filed with the Commission on March&#160;4, 2021 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;333-253851).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(26)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on April&#160;12, 2021 and incorporated herein by reference (File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(27)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an appendix to the Definitive Proxy Statement filed with the Commission on April&#160;14, 2021 and incorporated herein by reference (File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(28)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on August&#160;9, 2021 and incorporated herein by reference (File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(29)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as exhibit to Form <span style="white-space:nowrap">S-8</span> filed with the Commission on August&#160;31, 2021 and incorporated herein by reference (File <span style="white-space:nowrap">No.&#160;333-259221)</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(30)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">10-Q</span> for the quarterly period ended September&#160;30, 2021 filed with the Commission on November&#160;11, 2021 and incorporated herein by reference (SEC File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(31)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">S-8</span> filed with the Commission on October&#160;15, 2021 and incorporated herein by reference (File <span style="white-space:nowrap">No.&#160;333-260295).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(32)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">S-8</span> filed with the Commission on October&#160;15, 2021 and incorporated herein by reference (File <span style="white-space:nowrap">No.&#160;333-260295).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(33)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on March&#160;10, 2022 and incorporated herein by reference (File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(34)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2021, filed with the Commission on March&#160;23, 2022 and incorporated herein by reference (File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(35)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">10-Q</span> for the quarter ended March&#160;31, 2022, filed with the Commission on May&#160;16, 2022 and incorporated herein by reference (File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(36)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on June&#160;3, 2022 and incorporated herein by reference (File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(37)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on August&#160;1, 2022 and incorporated herein by reference (File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(38)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on May&#160;9, 2022 and incorporated herein by reference (File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(39)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on October&#160;3, 2022 and incorporated herein by reference (File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(40)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on October&#160;31, 2022 and incorporated herein by reference (File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:95%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(41)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">8-K</span> filed with the Commission on December&#160;5, 2022 and incorporated herein by reference (File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">(42)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Filed as an exhibit to Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2022, filed with the Commission on April&#160;7, 2023 and incorporated herein by reference (File <span style="white-space:nowrap">No.&#160;001-00100).</span></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx497484_7">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on May&#160;1, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">THERAPEUTICSMD, INC. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:100%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Marlan D. Walker</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marlan D. Walker</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated on May&#160;1, 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:38%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:59%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Signature</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Title</p></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marlan D. Walker</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marlan D. Walker</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer (Principal Executive Officer)</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael C. Donegan</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael C. Donegan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal Financial and Accounting Officer</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tommy G. Thompson</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy G. Thompson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairman</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cooper C. Collins</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cooper C. Collins</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gail K. Naughton, Ph.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gail K. Naughton, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Justin Roberts</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Justin Roberts</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>2
<FILENAME>d497484dex313.htm
<DESCRIPTION>EX-31.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.3 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of Chief Executive Officer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Marlan D. Walker, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K/A</FONT> of TherapeuticsMD,
Inc. (the <FONT STYLE="white-space:nowrap">&#147;10-K/A</FONT> Report&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this <FONT STYLE="white-space:nowrap">10-K/A</FONT> Report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;1, 2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marlan D. Walker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Marlan D. Walker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Principal Executive Officer</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.4
<SEQUENCE>3
<FILENAME>d497484dex314.htm
<DESCRIPTION>EX-31.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.4 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of Principal Financial Officer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Michael C. Donegan, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K/A</FONT> of TherapeuticsMD,
Inc. (the <FONT STYLE="white-space:nowrap">&#147;10-K/A</FONT> Report&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this <FONT STYLE="white-space:nowrap">10-K/A</FONT> Report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: May&nbsp;1, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Michael C. Donegan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael C. Donegan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Principal Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>tmxd-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 01-May-2023 [02:52:07] {PM}-->
<schema targetNamespace="http://www.therapeuticsmd.com/20221231" elementFormDefault="qualified" xmlns:tmxd="http://www.therapeuticsmd.com/20221231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.therapeuticsmd.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="tmxd-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="tmxd-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="tmxd-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="tmxd-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
<import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
<import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
<import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
<import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
<import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>tmxd-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 01-May-2023 [02:52:07] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="tmxd-20221231.xsd#CoverPage" roleURI="http://www.therapeuticsmd.com/role/CoverPage" />
<calculationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/CoverPage">
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>tmxd-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 01-May-2023 [02:52:07] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="tmxd-20221231.xsd#CoverPage" roleURI="http://www.therapeuticsmd.com/role/CoverPage" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/CoverPage">
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>tmxd-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 01-May-2023 [02:52:07] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName" xml:lang="en-US">Auditor Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId" xml:lang="en-US">Auditor Firm ID</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation" xml:lang="en-US">Auditor Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription" xml:lang="en-US">Amendment Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription" xlink:to="lab_dei_AmendmentDescription" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>tmxd-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 01-May-2023 [02:52:07] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="tmxd-20221231.xsd#CoverPage" roleURI="http://www.therapeuticsmd.com/role/CoverPage" />
<presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_202412" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_202415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_DocumentType_202415" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_202416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_AmendmentFlag_202416" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_202417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_DocumentAnnualReport_202417" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_202418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_DocumentTransitionReport_202418" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_202419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_DocumentPeriodEndDate_202419" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_202420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_DocumentFiscalPeriodFocus_202420" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_202421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_DocumentFiscalYearFocus_202421" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_202422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_CurrentFiscalYearEndDate_202422" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_202423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityFileNumber_202423" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_202424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityRegistrantName_202424" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_202425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityCentralIndexKey_202425" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_202426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityTaxIdentificationNumber_202426" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_202427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityIncorporationStateCountryCode_202427" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_202428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityAddressAddressLine1_202428" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_202429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityAddressAddressLine2_202429" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_202430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityAddressCityOrTown_202430" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_202431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityAddressStateOrProvince_202431" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_202432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityAddressPostalZipCode_202432" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_202433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_CityAreaCode_202433" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_202434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_LocalPhoneNumber_202434" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_202435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_Security12bTitle_202435" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_202436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_TradingSymbol_202436" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_202437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_SecurityExchangeName_202437" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_202537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_202537" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_202538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityVoluntaryFilers_202538" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_202438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityCurrentReportingStatus_202438" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_202439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityInteractiveDataCurrent_202439" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_202440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityFilerCategory_202440" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_202441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntitySmallBusiness_202441" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_202442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityEmergingGrowthCompany_202442" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_202443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityShellCompany_202443" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_202540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityPublicFloat_202540" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_202444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_202444" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_202539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_IcfrAuditorAttestationFlag_202539" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_202541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_AuditorName_202541" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_202542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_AuditorFirmId_202542" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_202543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_AuditorLocation_202543" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_202544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_202412" xlink:to="loc_dei_AmendmentDescription_202544" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g497484g0427043027505.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g497484g0427043027505.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  D /L# 2(  A$! Q$!_\0
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M!0YI6$Z;=S6C2'2-"!BC AM;?<J+Z*O2N \/+XC\;VC:U+KC6-M([+#! N<
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<^%%%, STH_"BB@!,T444=0%HHHH!BT444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140470548022160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 20, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-00100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">THERAPEUTICSMD, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000025743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0233535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">951 Yamato Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca Raton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">961-1900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TXMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,323,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,135,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">GRANT THORNTON LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Miami, Florida<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">This Amendment No.&#160;1 on Form 10-K/A, or the Form 10-K/A, is being filed by TherapeuticsMD, Inc., or the Company, in order to disclose information required by Items 10, 11, 12, 13 and 14 of Part III of Form 10-K, which information was omitted from the Company&#8217;s Form 10-K for the fiscal year ended December&#160;31, 2022, or the Original Form 10-K, in reliance on Instruction G to Form 10-K. The Original Form 10-K was filed with the Securities and Exchange Commission, or SEC, on April&#160;7, 2023. The Company does not expect to file its definitive proxy statement for its upcoming annual stockholders&#8217; meeting within 120 days of the end of its most recent fiscal year (as required under Instruction G to Form 10-K). Therefore, the Company is filing this Form 10-K/A in order to include information that would have been contained in the definitive proxy statement into the Original Form 10-K. The Company is also filing as exhibits to this Form 10-K/A new certifications with respect to this filing by its principal executive officer and principal financial officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002; accordingly, Item 15 of Part IV has also been amended to reflect the filing of these new exhibits. Because no financial statements are being filed in this Form 10-K/A, and this Form 10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. The Company is also not filing new certifications required under Section&#160;906 of the Sarbanes-Oxley Act of 2002, since no financial statements are being filed with this Form 10-K/A. Finally, the Company is filing this Form 10-K/A to delete the reference on the cover of the Original Form 10-K to the incorporation by reference of portions of its definitive proxy statement into Part III of the Original Form 10-K. This Form 10-K/A is limited in scope to the items identified above and should be read in conjunction with the Original Form 10-K and the Company&#8217;s other filings with the SEC. This Form 10-K/A does not reflect events occurring after the filing of the Original Form 10-K or modify or update those disclosures affected by subsequent events. Consequently, all other information is unchanged and reflects the disclosures made at the time of the filing of the Original Form 10-K. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>d497484d10ka_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tmxd-20221231.xsd" xlink:type="simple"/>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn04_20_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2023-04-20</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2022To12_31_2022">true</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2022To12_31_2022">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P01_01_2022To12_31_2022">0000025743</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="P01_01_2022To12_31_2022">10-K/A</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="P01_01_2022To12_31_2022">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2022To12_31_2022">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2022To12_31_2022">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2022To12_31_2022">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="P01_01_2022To12_31_2022">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="P01_01_2022To12_31_2022">001-00100</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P01_01_2022To12_31_2022">THERAPEUTICSMD, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2022To12_31_2022">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2022To12_31_2022">87-0233535</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2022To12_31_2022">951 Yamato Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P01_01_2022To12_31_2022">Suite 220</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2022To12_31_2022">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2022To12_31_2022">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2022To12_31_2022">33431</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2022To12_31_2022">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2022To12_31_2022">961-1900</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P01_01_2022To12_31_2022">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2022To12_31_2022">TXMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2022To12_31_2022">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="P01_01_2022To12_31_2022">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="P01_01_2022To12_31_2022">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="P01_01_2022To12_31_2022">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P01_01_2022To12_31_2022">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P01_01_2022To12_31_2022">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2022To12_31_2022">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2022To12_31_2022">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="P01_01_2022To12_31_2022">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="P01_01_2022To12_31_2022">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="PAsOn06_30_2022"
      decimals="0"
      unitRef="Unit_USD">87323238</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn04_20_2023"
      decimals="INF"
      unitRef="Unit_shares">10135323</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="P01_01_2022To12_31_2022">248</dei:AuditorFirmId>
    <dei:AuditorName contextRef="P01_01_2022To12_31_2022">GRANT THORNTON LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="P01_01_2022To12_31_2022">Miami, Florida</dei:AuditorLocation>
    <dei:AmendmentDescription contextRef="P01_01_2022To12_31_2022">This Amendment No.&#160;1 on Form 10-K/A, or the Form 10-K/A, is being filed by TherapeuticsMD, Inc., or the Company, in order to disclose information required by Items 10, 11, 12, 13 and 14 of Part III of Form 10-K, which information was omitted from the Company&#x2019;s Form 10-K for the fiscal year ended December&#160;31, 2022, or the Original Form 10-K, in reliance on Instruction G to Form 10-K. The Original Form 10-K was filed with the Securities and Exchange Commission, or SEC, on April&#160;7, 2023. The Company does not expect to file its definitive proxy statement for its upcoming annual stockholders&#x2019; meeting within 120 days of the end of its most recent fiscal year (as required under Instruction G to Form 10-K). Therefore, the Company is filing this Form 10-K/A in order to include information that would have been contained in the definitive proxy statement into the Original Form 10-K. The Company is also filing as exhibits to this Form 10-K/A new certifications with respect to this filing by its principal executive officer and principal financial officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002; accordingly, Item 15 of Part IV has also been amended to reflect the filing of these new exhibits. Because no financial statements are being filed in this Form 10-K/A, and this Form 10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. The Company is also not filing new certifications required under Section&#160;906 of the Sarbanes-Oxley Act of 2002, since no financial statements are being filed with this Form 10-K/A. Finally, the Company is filing this Form 10-K/A to delete the reference on the cover of the Original Form 10-K to the incorporation by reference of portions of its definitive proxy statement into Part III of the Original Form 10-K. This Form 10-K/A is limited in scope to the items identified above and should be read in conjunction with the Original Form 10-K and the Company&#x2019;s other filings with the SEC. This Form 10-K/A does not reflect events occurring after the filing of the Original Form 10-K or modify or update those disclosures affected by subsequent events. Consequently, all other information is unchanged and reflects the disclosures made at the time of the filing of the Original Form 10-K. </dei:AmendmentDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &*(H58'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !BB*%6N3>3_^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R$[H&";-I:.G#@8K;.QF;+4UBQ-C:R1]^SE>FS*V!]C1TN]/
MGT"-]E(/ 9_#X#&0Q7@WN:Z/4OLU.Q%Y"1#U"9V*94KTJ7D8@E.4GN$(7ND/
M=42H.+\'AZ2,(@4SL/ +D;6-T5('5#2$"][H!>\_0Y=A1@-VZ+"G"*(4P-IY
MHC]/70,WP PC#"Y^%] LQ%S]$YL[P"[)*=HE-8YC.=8YEW80\/:T>\GK%K:/
MI'J-Z5>TDLX>U^PZ^;7>/.ZWK*UX51=\57"QKX3DE5P]O,^N/_QNPFXP]F#_
ML?%5L&W@UUVT7U!+ P04    " !BB*%6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M &*(H58HT%QQ5 L  &L\   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9M]<]LV$H>_"D;M=-(9O?!%\DMB>T:6[$37Q/992GJYF_L#(B$+#4FP &C9
MW_X6($6*#@1)-U0[222*^R/P8!?<!<&+%>,_Q)(0B5[B*!&7K:64Z?M>3P1+
M$F/192E)X)<%XS&6\)4_]43*"0ZU41SU/,<YZ<68)JVK"WWL@5]=L$Q&-"$/
M'(DLCC%_O2816UVVW-;ZP"-]6DIUH'=UD>(G,B7R:_K X5NO5 EI3!)!68(X
M65RVAN[[<5\;Z#.^4;(2&Y^1ZLJ<L1_JRR2\;#FJ120B@502&/YY)B,214H)
MVO%W(=HJKZD,-S^OU6]UYZ$S<RS(B$5_TE N+UMG+122!<XB^<A6GTC1H8'2
M"U@D]-]HE9_;[[=0D G)XL(86A#3)/\7OQ0@-@S.G"T&7F'@O3%PMUW!+PS\
M?0WZA4%?D\F[HCF,L<17%YRM$%=G@YKZH&%J:^@^3=2X3R6'7RG8R:L1>R8<
M/< 0HP[Z.AVC=[_^?M&3H*Q^[P6%RG6NXFU1<3WTA25R*=!-$I*P+M"#)I7M
M\M;MNO:LBF,2=)'OMI'G>)ZA02.[^3#E73#5YK[!?&PW_T>6P-4=T]5KO?%+
MRK[6\ZV4_S.<"\G!T_]K(IPK],T**OS?BQ0'Y+(%\2T(?R:MJ]]^<4^<#R8Z
M38J-&Q*KD>N7Y/HV]:LQ"S*89B2:O:;$A,UN[CJ=/WI#$R&KW:&$&A*K$1J4
MA ;6+@X!3Z@1W4;XR83(;B]Y9@([LEH="J@AL1J@DQ+0R7XN-$R2#$?HD:2,
M2Q,HN\XV4%:K0T$U)%8#=5J".MTSUCB&&[N^+V^'9==:X$@8:5G-#J75D%B-
MUEE)ZVP_6@^$4Q:J.Q^"6[!QDMJAM+[7;;W96>T/A=:06 W:>0GM?#]HMU0$
M$(L%NULX+$S@[&JWWTVPK#:'PFI(K ;+=:KDS#D(UW>"^798.\2V.9?=[%!@
M3:G5B6VDLZZUDZ.,\[? ;)&Y0Z[3<;V.[QJQ62T/QM:06AV;5V'SK/V\2225
MKT M(N@NB^>$&V'911S'[< ?QS'BLMH>C*LAM3JN*IUWK3GO&M<C>:(JHP=_
MN\.QV;_L0K-/-X_#AYNOL\EH^F7<1I.[4==(K]&$OBFU.KTJI7?M27E!;P1Q
MRB%&)U ROJ _R*N1GUW*4?]Y@].^J<@;V8T/IG:,+-^MTGS7GJ<7U&;X!4U"
M0$<7-, Z1[,$K%WR[+0#Y;$_\ =&>HU6 $VIU>E5-8!K3]X+>I,D8!PR6@VN
MC:82;@N(<31B&3@C^"0+S6%L5[_[9@38:&70E%H=8%4;N/:$O@ X#$-0%^WU
M!_09SD/WB9F:7?)\X*+O.,:2H4>&0R/"1LN%IM3J"*N"P;7G^5:$LQ4S(K1+
M3C,*#NQYYEMNHV5#4VIU>%7AX-IS_;?P1NH;1.Z,K1(C.+O<-0LP>@37,QF/
M[,8'DSM&$>%5181GS_O?DBLGO0?.GFD2&$-WA^;M9^.:;*.51%-J=6Q5)>'9
M4_^WV!Z8D)"M_)NF6^\2.Q1]OV\N)>QV!W,[1BGA5:6$9Z\"=& ..<';,=D%
M!B=F2(T6$$VIU2%5!81GS_L_,[WZL62)K=[:(7)^XG;<<W.Y93<]F-8Q"@:O
M*A@\>Y8_HQ+J4K9 KO=N_CN:DB#CX&5&9':E$8MCR)BGD@4_VBC%'#WC*"/H
M5Z<+E2M*"4=BB;EQY=(N?3#28U037E5->/;4?\9Q2),G-'V-YRPRDMPA\*\O
M8R.E1JN&IM3JE*JJP;/G]6M/0S<OP1(G3V1KG;]#Z&XX'0__:>35:)'0E%J=
M5U4D>'L5"7^2*.K\2" S@UC% B:Y$$V$R+;,<G;-.U->/+(;'8SM&(6!5Q4&
MWEZ%P3<6016*>;X.QXUKO#N4ML!JM!!H2JT.JRH$O+T*@?5";_Z 2D]ED->:
M%\9W*'XG)JN1W>I@:L<H ORJ"/#W*@(FB20\WVNCEL3Q&J-Q0X)=<0LUN]7!
M6P^.40/X50W@[U4#Z'!$(RB;GA@WIAT[=.Y8TL%!0$ &1,)<T$BOT4J@*;4Z
MO:H2\/=ZJ#"-<12AZTS S\(8GSMTMCUXMYL=#.L8%8&_L4-HKT<*-S'A3VHV
M^P@*<@DU5)SBQ.QS=L&M3^#M=@=C.T9IX%>E@;_7LX3I$E(.*RR[S'98C2;]
M3:G5855)O[_7(X2';![1 -U&#)LG_B93^%&C:N-";:#5U*;6YZNS4]^#_\\N
M>L\F.E6R[^_UB*!>(DY5-2C0?2:%Q(DJF8S$FDSB1X7:R48?7<?U![[:ROA<
MHW&,=-^OTGW?GII/1K>/:)B%5#*.AE(28*2?2&W;B;9#;WL4-IKM-Z56IU9E
M^[X]1U\#VU9*[C#_^#B\FZ'9I_O'N]G]'?K\^<%(K-&4ORFU.K$JY??M"?J:
MV"WE,9J8EAVN=RAX_3,CI493_*;4ZAMEJQ2_;T_(UY34VJ**0A.F'1)?*(YI
M6]T9. VQB9A=X.!]L\=([_M5>M^WI^75UMDQ$0&GZ59L_T<B/5M2@:HKW+%N
MWG(7J0F2@2?GFY/;ZE&,7)+Z,;"=$Y4'+J!4"-'\%<V64#RD)),T$'JK2!)T
M2]LB\P&[! Z%4*U(AD(J@H@) @?S%T3R=S7^SBC/)2>2Q (NV4:N"W\\^.,C
MN,LAMZ]66Q\PEV@RF:C/9>/::+6DP;*FN<("L9A*5=HL.(LWF_3;+V>>>_I!
M5 IH431ZD>_1>E5[M(AZ;P"&(2!J,3PGM=[^7_;RGE/(C<%DHS54=2FB. F(
M CM)!)0+^3LE'Q6$\M2N(FB0T*W/*:\H9-SJ0L6Z'X4[O\)1KOZIW( *H?<.
M0)NF-Z.VNN@PY33*VWR:OW*07ZQ @$(&0@F3B+RD))"J6>J"B$JAWE&A"=4%
M><K9RRM2]U"B749Q4J=D:0!TP1=POH%9J-1DR2(89E'@13$A>A%$=0&0N)Z#
M0OPJU-"I#@%>]5&IQ4Q(0!;H*VR,P#O 4#I'EB@?V@[S=]U!3J")I+TYW,IQ
MH6^J*5(%P(93UWR3)D&4A777E$LLT8IE48B6&'C,"4E0P!*)J5I!I(F^D 48
M34#9["CU 8&&0:K!UBV%GI.7)9TK/%KA3<,3LD(!X=66&Y&["L3Z>CRU32$'
MD:64P"F2@*;0"O("_J1;S!8@ 0245U6_0X? ?RE\6O^>9EQD:E\92$_S5Z2*
MF'"\]9A.,9]C**D[]R\1>45#: C\XCF.]P'A( #4T)@(Y@05YL@=5"']#?@6
M!#1C'.?A!Q>#(8UTEW1\ZN[DEX-I1&%8<^JB:Q+@3!UE&^TOQP+D.:E-87KX
MZF#;FL-/N,MP*<9>A9IN(M+!E,]J&<B_'81\/O.=4ZWK.V>J[8_D*8MR!YNJ
M"2/%'#_!3+J$,]NHKT\=K)F^&>7*#8OIS>Q&JJT%+(.KO FJVG">.R>[A[.-
MA'I,OS?I8AJK4^U"]@01H?QASW!5=Q 2$4FT 3@&Q'LQRVI4^IVFHO&&:;4(
M1;JYXTJ%QH;0 NFU6P6IF)QV!??F+6E[H+^==P2**(Q?[H0B8"DI6Z<]AA;[
MZ> $/(=N:9\02ST3S577L;8$=_PK2_+IL+Q5&'J>._7/=T &!WF!6VS<;&Y&
MAD:70;".2/*L!YL%<&OB>M9:2,)_#E13BR" 8A;2A=XQDZ4AUH.J4H,JFL"/
M%@NX4)X:B&PNP&\5^/S"7>A.4AQ23J36]/(.;4[AT D@I&^6H>90M%[D4_?&
MQ6(,LS_.)QI)8[)N_:Z^=)$Q+6UTW;0IM3PM[6V\G:E6]_1;K@*\*4MD_J)F
M>;1\DW:HWQ_M5:?GK^%^P6IQ$-R9+,#4Z9X.6HCG;[;F7R1+];N><R8EB_7'
M)7@OX>H$^'W!F%Q_41<HWR^^^A]02P,$%     @ 8HBA5K+WPF_N @  B0X
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ 8HBA5BC07'%4"P  :SP  !@              ("!#0@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( &*(H5:R]\)O[@(  (D.   -
M              "  9<3  !X;"]S='EL97,N>&UL4$L! A0#%     @ 8HBA
M5I>*NQS     $P(   L              ( !L!8  %]R96QS+RYR96QS4$L!
M A0#%     @ 8HBA5AE%%?4W 0  )P(   \              ( !F1<  'AL
M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &*(H58D'INBK0   /@!   :
M          "  ?T8  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( &*(H59ED'F2&0$  ,\#   3              "  >(9  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  "P;      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>38</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>2</UnitCount>
  <MyReports>
    <Report instance="d497484d10ka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K/A" original="d497484d10ka.htm">d497484d10ka.htm</File>
    <File>d497484dex313.htm</File>
    <File>d497484dex314.htm</File>
    <File>tmxd-20221231.xsd</File>
    <File>tmxd-20221231_cal.xml</File>
    <File>tmxd-20221231_def.xml</File>
    <File>tmxd-20221231_lab.xml</File>
    <File>tmxd-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g497484g0427043027505.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d497484d10ka.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 3,
   "dts": {
    "calculationLink": {
     "local": [
      "tmxd-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tmxd-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d497484d10ka.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tmxd-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmxd-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tmxd-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 39,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 38,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "tmxd",
   "nsuri": "http://www.therapeuticsmd.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d497484d10ka.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.therapeuticsmd.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d497484d10ka.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    }
   },
   "unitCount": 2
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-23-130656-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-130656-xbrl.zip
M4$L#!!0    ( &*(H59J!#,F-*@  .CI!@ 0    9#0Y-S0X-&0Q,&MA+FAT
M;>R]:U/C2+(P_/U$['^H8'?.H>,5QC?N,_T$#70/N\WE +VS\SRQL5&6REB+
M+'ET ;R__LW,JI)*LFQLL,$&3>S.8%NJ2U;>,ROSY__SV/?8O0@C-_!_66O4
MZFM,^';@N/[M+VM)W-W876/_Y_.?_NOG7@P/PL-^M!_W'YU?UGIQ/-C?W'QX
M>*C%/1'R@4ABUX[Z3LT.^IO->K/9:+8::^H=S_7O<N\\=D*O%H2W\&2]M8D_
M=W@D]./XJ^.F+Y@/;V_*']-'1X9^:-&SC;V]O4WZ-7TT<LL>A$$;F_\X^WYM
M]T2?;[A^%'/?SJW%G;#VXO..*"P\$G;M-KC?A!\(+OI!-PK:S<;.I*'E$]G(
M@U#8/!;.V'?V-GEHAX$G-K.']>MVD/AQ."Q?G/HQMT ["4/ AG%OJ%]SKXA'
MNU?^./Z2>]3G@"[ES])/N8<CURY_%'[(/Q@/PC%/PB^Y1Y-HXY;S0?ITET<=
M@J/Z(??PHS?AG/[QW<"R) XG' _\6IA_(TH& T_TA1^/70H^0\OYHY5N-(PG
MOJE^'WVK]-$\8CZ.VT #T1U(2OSCR]7W[/&X_/GLT<TXY'[4#<(^CX'3X&SU
MC7ISH]$TJ6P2B(L< B;=@)/-O:%/>M*\C:V-^NY&RIC&,PYD>&O$^01W\+^Q
M&WOB\U<8BS7J&W_;//QY4WX%O_5%S)D=^#$=12P>XTU\_X#9/1Y&(O[EQ\U7
M9*4XV8;X(W'O?UD[DH]OW P'8FT31]G44W4"9_CY9\>]9U$\],0O_^.XT<#C
MPWWF![[XG\\_NX_[^*P(Y9^NXPB?_H3?SY.^"%V;^;PO?ED#IK-_"!CB()9\
M]?CMFESG8WPENK^L7=8;_X+_X>G?!(WFOUKR[[7/<9B(GS=S(XZ?X#BP$QK?
MC6SN7<*O@?,5OHNFG.SK[U-/=>(#T(=',%G(O5/?$8]_$\,IIZGC/\VMG79K
M9+K-/!A#T17(W$3T^6?$O/V(9 ,,STBB[,=P:+^L16X?Z&]-?=<+<7:4CAM:
M_-4>(V"_FVH0C<,S#_,O8.4UP%?]"#+X";1"_!]>B0!*A/??LXGU$$I,3!:<
M,$@P$&'LBFA41$\O=Z<6_B\'E".ZLP(*7G%]]V.!R>.=6<$$KPCOXT (^-BL
M$()7[,1;-8+;++ [^A@%24B?2/G=5]R5N<YX[LH^,_6T(!:=?G0=_*+KBI 1
M%Q6E,OOH]&]Y!EU\&<;;+!U_0.(F_0C*>!@?@][[&9>U46_ __2;V6_96IWL
MV483%(-L%D<]N5F89S,'E%(8'487?GW[7ZWZ<L%&FBJQ@LSV1JN>CJ5^>?YN
MV[!5W&UK&7?;VJBW@;:?N]L$Y -M]0?\\:\?U\?&'ON"1TDH/BM;;1]^U:/H
MG])A<9SR,2/0$T54,JQ"7/KYB7$W\Z2[:2B)FZ!+DD)I:I5K'6[?W89@^#D;
M=N %X?Y#SXW%0:IL2CWZ8"WW$L)E@WONK;]O _Q%>$#?N#Z>SSZK#QZ?>B'_
M\X/KQ+W]W=J6ZQ\8CWJB&Q_T>7CK^AOX]S[C21SH;T+WMJ>_>F)ZW,)&3\@7
M&H/X@*DQXF @G]=?=((X#OKJNTX0 N32[QJ#1Q8%GNNP\+:S7K<8_N\33/7?
M?VYLUP\R )=.VWJU:<U)VL:LV23P71>P>R-R_R-@@MWTBR[ONQZ<^G__D03Q
MP8W;%Q$[%P_L*NAS7WYYP(P38NKX\^"FH1[DOCN!YZ38E"+3C_/3FY-C=GUS
M>'-RS=06)FZDOIP;N3XY^G%U>G,*NS@\/V8G_SCZ]?#\VPD[NC@[.[V^/KTX
MG]_NFJ^^N]]XU'/]VSCP+79<.ZJQ9GVKO3=V1R.+G0;=Q^/Q$TPC1UW;V70T
MK&0+HZ04EY$2D_R'-1L_C0%;;HD33S*W\25"U*\75V<LQW.1SV]$ VX+="D\
MA'QPP#P1P^#T+9R[.K3T^$9'S9W'K.\^Y4D@I\AT5KUVQA0M^NR\YD>&]5<_
MN_74></.@YK$Q<:GB@SGOV]T\?&.)V!*SQMP1\9 ZFOT66$V?593?KFX.CZY
MVCBZ^/[]\/+Z9%__D4>0 F:8Z$0+E>#9KQ]( #3J]9_(ZQB'>IX!OQ4;G5#P
M.PQ-@!J\S^\#UY%/.7DUJOW3P3V:CV"**@ " $;4JBGH[]#W$^Y=B4$0QM/1
M(9->UE_6E&<6\#GP.MSS@K@3/"*H]W;:VP>C=!H[^9U,MX$W$J8T/<OAO8_[
M]F8F[,/S\Q^'W]G5R>7%U0V[_'%U_>/P_(;=7##0*VY0>6BTV,45:VRM.Y_8
MQ5=V\^L),U2.5-TX/+K!GQM[K7:>+2!DX5^H_A-BOU!NO3[O^QJ$+.X)UB6W
M,AL*'C)@AL)A"Y4]TG]](NW_V9%_WX'7-OKP5@_'WG#X< .7OB'\"9,?431-
M>=!_A\?G.C].?2QLT>^ [8T^CCP16FQ*USXN;!;'/OZ[U-<^(JFGDM'+BJB
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M6&Q94 RBT61T^3IBZS >J,LL2NP>6) !WEG0%P3C'H^+NWC@T2CQT,MJ(Y^
M8?L.6V\:N^V Y@T/=?X->\&7Z'EX$Y>B!L-[LQ&MA%;*HYCMU9G#A]%XJGH)
MF:B[[/*"+MIY,8^GOC+^.]8YFY)<QBW^/"CA"$M(6[,A.9XV''3?!4IRF/#@
MP,/ 1V/5&S(!ANN0G:(^QFT*UQ_SF,N[@P7TS\8P&;(I^Z_$K2ID.3?=;=[!
MXNN-F]&17[+"=?RP<]!L-6NI!@0"#:A^0%>-%DSK\E!2ZA71I\70IH$AB""*
M5)>*-E>+*DG%]F!5@G';!JH,L>8^G2'JUW[IMTM+5G"R&\:"YTMB>O<LZ@//
M E"&6D( ^O4'W!]:*((!9B"R\)AOV6T8/,0]_7,-)+*@ \B*-E.Z$B8'-.L'
MXXZ!?FX<Z,>>?&#L^O1S*(75LV.6JI]45M72'GBCV=EHSO>8E?)D:DS[[\XI
M,VL:A/*WV('G\4$$R]%_S>("'&%TRCVSV]C.BH?F$CE*KJ#FMEXHZ6),D/U:
M2%%@C>U6K;&[2[\_Z4!G*I"8+K76V-IN;HUY63W4;N_6=N&\%C?#XO?0V*ZU
MVBUCAM% 7R[&QRC(]Z3L&L&!R8$^O?0G2.8[,DZ)ZH<9<Y1?D*T[971ERNGR
M1#6O,7.:Q#P7NHCECH"YNZI@'L5K$T5',=1T3C_%R8M+!Z8)[,O_9:VY]IZ'
M6V96,?^TW\4H-E.4K@F/@/QN@W#*_C&CH4\:B0C75B/1=?.\#LT499?&/^<<
M&EEROK&],NSY6EH <NC4#) ?E8:__#!_B9^  / EB>#A:$K7W;,KP);E %0"
MY:,(E!-E0$L*D%;T!R(TO?UOM/$CN>4%5[5<E,A8"&R7__2G2%^R/<%#3#[K
M'?3YHT[04,Z,Y7![OE6@KSO!X8=W>Z8,/F-TA&(BH'%A%#H.6!))9R'0D2P;
M75*G,PAI+F^(DS^X,#5,RWS89H#^OWLW(@W.Y[[M<@]]BUB?"!_&%D(.#YV(
MX;U?UYF8M=1:YVE4T72,U58C4+4206 C]JL\MYB C:Y:#M-&LA4B'@V6D(-E
M\EN*C*87RW@4@:Y#K1;428EN5U"HQ%?78O%-%R,H/N "LN@P\%@ ;,- D<QI
M3"52\XC0KK>-NUK7/.QP&'OCXM$30PHMKS>VV(_:-39<V6ENX\6N3[C[;*LJ
M/:[C@2PQL+'KAGT9:!K  C@^! A,:3X.+9LGCANKQ>5#2\^37J=V-SS$,8/P
M, /O]!U&YR*\*A(Y[<I#C+)4!3A\;;>4Y5/*WQ16,KH[*+\*U%" :]H5&%OR
M+X,+*]4,J5'^B20I_S+H4ONT-%%0?029AS RC1E,HYN<E(Q6>$AF-.@7NLCH
M"T_801BJ3>DIN!I%A&&@;#F]_P'R]B")O*$FDK+%%MCS<C/ITYD.B6)4^6,/
M(C$"KPRJ*LO*P*X,3GH$'NO?5&2;Z\\V<LFA/A;N#2,W0P4LO.$CG]W MI0.
M263A1Y)A8[ =?G+2;96L? 23-%-7^RG4, @C(YRO7_7$/:*@7JK6$#3E+&T$
M+S8"ZCL'S7:]UJ@?;S2 K%<5>Z>-ND<]X7E:563KH[FL2WMFKQ-UG9!",EO&
M;CYGXT5N)3RR9QNY^UWW43B 8UXDIO0G+05N'Y+R^-?$5\RF5;<8;LXJH'6J
MBO:#B#@1<$404&2@"#1L0,H'OJ,;XOR14!ED.0J_O86!D(#Z\M*-O,.FT.(^
M("T1E.&EI0E,/9'+G"]AV/)V'TJD>,@ _U"2+#44>!>U'3C*:.Z0&"2Q3'U-
M6SZC0808HK!F "0$R!2KBZOX2QZ F+CF80II%  D\=-?IF$(7RGI#(8I<H1+
M,F6^>@$O9J$5FRACEUOZ)>O"ZPC;[0,WD)D60!."_C)9AI_T-YR >E?@HU@I
MUFHU6U:SM:LYAUZ;8A>U*7A'&>LH<(Y1QE%@&YHO' +,/7E.3<D86D32H6 /
M^*\@B<G7@ 3\%#3E55:Z?'=-/8,OLI?+P&MT;<Z#5S<DSB!\>OYU:A@WZE:C
MM85P'H&QO$H;:<94POP4OD5/7<>MS=Y9H<HG6L)\HN;N5FUKK[W 7)SF=@.4
MXKU%SK#5K.WM&GMXFX@+7E=^2A>1/AOV%1U&I\X^6[\\.KSXPDZ/58\9]CS]
M3HV+PYXZT[:':^^6:V]I[;6WBT[, $J\/;W_,K#-T!#DVQ6UX?KUXNK\YN*<
M??]^N:P!GAE B$709%^I%X%1#S,E*,]<H#R+356K<W[1G1&NNT 9]2R?XC@9
M-?:><6/:74S=W_[U+Q2/VUMKFKV57ZE>QKV!FA" 2,_?\IY!"O6%XR9]_16.
MF=;,D=_=\] %;6X#6 "/$]#TQOQN@[)2^$F5)V#M>GT4:?6303CH<1]>;>;O
MHH.6&\;J*]?'JOX:8/@-1?Y09<6! %BL8*S)L4&8!P]RZ <XS +D87V=.Q?&
MP@%!9PWNQ(82_]E$68N\C1@LJ#N,'&'Y(C=V<8;B,PJ"8W]7QY7^GG-?B/XH
MD>%W4M/H"-@OC(WEA(PHM?'O7IC'BC_OT3\'"O5;L"FC^>?FC'@TA>8Y-_2I
MD*4,64Q!T*HU=XWZCA*!:ML[)3BDOC[(T235#'F*=W'6"U'@_AE,M]12\1//
M.QB!]-KG&S)WP P\0E'MQ]'/FWR:NA=E';@D9'=K6ZX_TH]5[0[_WI>6B_HF
ME#N3Y2/'^0B7M%_:R3\NOQ^>']Y<7/W.SB]N3O(5/\=J27WA.QBP.1:1';J#
M&52E6?T@YH&W?YK1+W*#-R_3Q6)3%I5&@0']KT!_\V^#V:AO_&WST)( 9.JJ
M]&M,Y>(5;AG!5[?2;WH"QA4)Z-(1=?SS[9JEEW24)<8PTC?0?P=3V%X0"?A2
MNF5DW$S%X&#(TUCT(\!3BS4:\/^FA;U[,3.BT48*O 1NR$Y/3_'OQ>U9[UAZ
M%LVEHA<Q4'>2L7.NN=/4+;2XA:EU=<>VF]>MTY7WOJ&]]^J%"^ D+F:$+!YV
M+IZK!Q+0INJ"ISZ(ED2Z K\A)BQN!<HKBMCY&AO6N)+F]%!N5J$H V)P&O#*
M.N;2P5R?'%D((L.[NB.=JV5^PU=@:2E&,R<0LE**>!RHJ@U4Z@'3=/3%UGN\
M9AX\#K-D!,)/?"09V$ L%,WQ$TI7".R['H@)$4:*6D!-%['.:',QRT/6>T@3
MFP!P*IW)"#7E,'_=O* N,YE>$=L^&>@6DB)KF4P!N::J<4&W]!?)J#/*2_FM
M2E/)\3#*O7H($L]A/0ZG1W4Y4+1R'9$V[RV7'*_KJTC,*U"72<P&2+D7!1JN
MF$[YV',[B".TL-<!,V9>VNA'TBW9(DGY8 EH6J&EJ%6";,,%CF]7$1*3R'[/
MLGST[V.3-EOUYH1$/?BE6:^#\H])>"&ZZSV0RBAH66,K$ZI_I[1$ BQA!.^K
M5-2 J30F)7-H.W(Z$.0(!@W^&OLB;([)K'Y0FJ6$&5\Y)8*0;<'GI242@O>U
MD"-EG(JNJ%H  I22=I46E&#<K( R4O]IU7=HN:WZ;K[*R?R7?9V)[ $/^2T,
MTH,%6*Q-*T@KK!50/>,<2AVJE9(H@D!A3 F]%+AV#J?WZMM/X[3%(LS(FAK=
ME&A>, YHGO45>2/2VMO* U2[!69EJ#"F#J<'O@J:8U:P O7KZ4M*A.0;-^;"
M_=C<!_.35>6,)W0.$DJF>?#* NI--+574B@BYKE Y9)?1W8P2',Q7&)7KFI-
MBFF4'4 GXAQ1CU2,#J(<IS>!%_X[\:56EBK)KX=QDO^/FFNRLZPDRLC0WD^.
MD*>]LKS0HE;<RQ1D&TP(RO_DW5B$HQ+X%>$'(JP?.&YWB'\E X<31T%C/I-G
MP'+I)H(TYJ.D$P&+1_*4^ZFA"TU]A8P12]])\)L**H <T(1L)8=.30$EDHJI
M,5F?.Y0"A-_';C]-(GMU$!6X0"$^QT9<9LH=M_N\SC:3__VG_V)_^J\__=?/
M@S)&-.I%)4>\4<E?>>.Y]P!FV!IN:8#!T]E<\&SSLUS$:WI&8>.EFR[QC,Z:
M 74PXN@<W0VP0=AD8 -C/OSR_81=?&5'%^<W)^<WUP3$\L7-(S]KFM5]_ADO
MZ.;.(G/([Y,"AOB\]CF5H3]OXAN?"TLWEH4K+X!Y9!\9X@X0(XS4(3-5J)A*
MI.9ZQ?[%1#2R+Q,K29O9_BE-J6&3,@ER392:^J6R$7=WYS#DY+\I"X MHF/'
M% O.-2Z8X?GGO;7@67+WV^D78(.*KBX!I,]:KDJ\TICW%D=DT#7+4S(KY4DF
M'V[4ZB0Z3!5V0W\YDQZ+-J\*F]1KR"@6C3/+L6TC"/G8WMMI[[;_U5C[?.SB
M+:8@C"QVDGJ(+O1E(-2&CI3!)-@W--W0[!4R(KEXR,U*-XI62$R#IE3&#4?[
M-DU).A79I&33^-ADTUS[G-'*D7$E;S7(8J\BB\601?-CDT4K[5DS9!<//LB/
MGCN@/!;8"#JEOPA?@&!!IZG\G>3+65IP@#Y>"8^*@UUGP3MX!$WD:#7(JU'1
MUX+HJ_6QZ:N]]EE3$A$)>JJ!PJ(<V=Q@BIZ\413)I@A:PV.GL)X!!ME61H%K
M-BM26@PIM3\V*6V!'9U&O@]EL1B,='\5*GGF6H3W8 *MB,AIMN=*)_HFQYNZ
M-V=T(/X]YS_\8)Z_QB3/WUY]#D-.X?FK'$L&?]WZV/QU&RUDE2.%[/1KFBUQ
MG4;0K^V><!)O97CL]CO113XL4NZ ?0H+E;=G5@/I6O-5@&&84=%N@+48'RX7
M]6:,#4<LA(*K:/";J$N7AU<W*H[ZJK%?%8<V0@JY^ I[7H!APBZV%[&)+ ZR
MV)EEOGLW\+S@@9+R2$N-A&Q#B/5=E86?O[!RRRF15B;0R<YDS$E7K/).CG0O
MJ'<20M_9?H$>W7Y6O+M5IO6^8(#"FMKZUT6H +M3:@ 'H_)C=J&=O]*-$CKM
MD_WG.OUSP'3F$B'0!B),8;FSTBC6@IB/S,['U/4@4VQJG$YEVJJC"S_$D+VR
M3I=MZ5-+K4:>U<U\?J5"*Y!5I]-3?<,D!=CVLBBO-T&_/V3?,!\4>'IDP&=A
MFFH95RBFGNS67W\-GX]ZW 5!Z&LI]R4 6:C&C9(2(;>S]=,!*SO;]>8GH,)D
ML#@6O%I8=A0$6#+L"+-D/0]VO!Q8UFZ] 99I]>]YB-7X5.%6'K>^<==C?ZNQ
M<YX _\>;IY>]VO$K.,6FP;#MG17$L J]#/3Z:Q+%& 8-.K#$9>%;;R$=%\"W
MGG(2/=^&G*N-F%J&IN/GB1J1TQ%-D0R4\?9348-&&&HD0/Q69#JBJM-O\Z2I
M63P=!6?6VN<S*MA@^@S2@O)4*"".A9 NA)* X <ZRN:J'255^IOB#%??,31K
MA'5V-TY[DAL'^.G:4EBK10GTA!?BYN+L['=YA-]4W:";7R_.+J\OSI5WHA0W
MBG7^QCBT1[#30)81%T.)AI ./6_'>*D!.=9%NLR[?2I)8KQ7FUWCO?5]?<S-
M>J/Y02!P>)MM&_T7*[CIJ9!<L_W]B6LIUB.=QP&0W'F."O[T\T61NN"PVMKG
M+VY %2EP#>PT"\&,Q9MB*?6G(Z8+VTZ)VY!%(L0&05Q>92[EA/@A"WY14[@T
MM(2_!4F8=I*A$F1G?*AK\C>:#+NL>0P&PX)4?# (L L<S6A<D7AZ7ECKM1C$
M1C&Q;5E+K,:^XJ1_3;PA?JZK"<]X:/=4L;%K88<BYN%PW+Y/$5'=/KL,142U
M _1"?OBPO##"A'7XYC<WL@.0U_#Z,(*EU,I&IC(C-'R4@=45W='@)@Z9OO8K
MH!?>][< NCA)XJ7-Z6KL4(XCHY\2ZME:".9_Y7Z"RVCL[>Y0?2G1">F+9KW>
M*(4 'L= A#T^P#)Z4<SNP&3TJ506UA@070PW1K+:SKT; [W]1Q;LR&;&EBI!
M?VBE+_E$"T 9GN".3N^'J837Q<HG5(ZJ+Y..]2L/07@'DSS@@8O'@6K6T!/<
MBWLVOH3]P", I1T&^!_/ ^#>ZGYH+ IL5\3#%$0X@:S<HO:K#[)VK32:8^SQ
M%^M>A;_21,K:YOW! ?LU0434Z9U4$.W77Z\M">8<6!$V&N[P>6L*1), 2BL]
M()BHEH)S'U ')UU(3^Z? *6!!XO%S1_2#7[N1Z7(1S2&=7-BGVH8T& >?Y!-
M#K%CQAU\^2WI#]AU'/($(/HK3S1%20!\Q3XOW[]?TM;3YRU-VY*LZEOYW6-A
MQ(>>\!E5=(F -ZM*38F?;@J[8]"]#>S/ JL'8(C2760PX[Z1E!Z/\(ECX04H
MU-@1B1J:29XHNPZ\1.>XF^ADT%;:*37;F>9;<GO R'"K>X!=\=3SJ;:9)N1*
MMMA)7(^:;)JT!F\!JN',)E4XXAZF'5#CU'025>[$W%@/^Z[[MP#:+AE;*:HP
M$@<N(G-'M27'O[%9"'8NH1^H;HVZ#Y A*AT!G&O@E1]46J KC^4Y-OH]P#8E
MKATI2.FJG%PW?R5VAL6Q;6H!BA1!! \K@7F$1[5;]+6A*#O6$8(LHF1C[)H-
M!$,\=+&I@\",BQ17O[A(1&X$T+L,/-<>JB/'=><4RC*?&W8B@LUU4>N1BF40
MWG+?_8\$:C>P$^S5AVB032-Y $Q$5==HSCX''+K5-:64A&NTIA$['"!JVOX=
M+5&SI!#<JB))LVYJFFV#2_U_YX?7QX?_N\]^W/QZ]4]:VF5O&.$5+4#"*SQ0
M6$.8@/CX?^>_@]7.CB^._OG$ IVQ"XSR*T3Y..P+=B/LGA]X@$B(HH@^V<)N
M?C\[_:?$A</D%A<"("J*0&P.=%1C5S7V!69)AZ %?SFZ*KX_@DF[,@T),< 7
M!0#1($?G1WH0+)I9,@;J(832L'>@>=@?XCN<J *)*GXU!@RR)HWJ72OY%L"B
M-E;KW%X>K;-$B?Z;&++_34"CR"JOR7JDV#A27CYZ?6VZ,;,V_1O6<@.^>B]*
M\#V5\2+=%<IC=8215"]HVY-/WL>2/4$2C1P^]7<"@DT\'@(:H1Q1HTIHHCKG
M"><6Y;&\^34J,US? 8R'56=\W@*PW G$T3ZJ'J!M):YZF3 5EXL:_ZB*7DKU
M60M20&%:Y)=4$\-5_K5V7,L*%X]1MS?.0"C :+5B%LA$EV6S7;DL39?E]GMT
M61Y=7%R>7,DS/%)XA<=P>GX]R64Y'7]<%1=6/L:7\^1EAOA*>K9>YL[#1)$5
MW/1,[KRHZ,];C3U.<A.^JG,R7YWC(_DHY^U<',D6&S&UQGD-I7UCZ.N-9HV=
MA9J=EXXVP:?V%8NT@J+A!I<]#GMGW[\?I384Z.\P_E;)^,6QT4$2B]NA.?2E
M"'WW,6\O99Z[O&5R>?./?Y(/1;Z4NAFD$:?<E-I<:+0MG!FOPV76,QD=8_8Y
MZK-H9*Y/.84T./*0SSEQTC=,T+=+0//O@"JQE^S>M.:%(]!5%QB0HF8;LC#R
M [5E+?,#&\N#IPV/VHY5  C\K!M*T.^T07QD')1P/'GD]5U+ZL?^K?2+89W0
MN!<*T/8XJGK4%B'O.\;;*>1<-B<ENRZW"FL2+OT=U?R<0^2+\L%(:SH,G,2.
M84!R\FBWY%A(ZR/%3=^(,,36?4-5(46=KKFV5G&Q98B/!R+Z R\8"D<Y0! L
MV,L@PJJIJ)F?:\_NUR"(.^B(_"[X;2)@2N[;H->K+@/(#RY"3Z![X)K#$4>$
M M0N03@NE\8(F7Q.ZH@=;\=.)\(J.W9>=FP1-W13#"P'[Y*S9T LU2:<!'30
M+#RS-A$"62L!P_I5[CY5]/N/Q 4[3V G=@-^0*-W+MA>%H8FJ 8]#*+<DL90
MU#$"[=3,3%7C3&FI_M;#KB'HE0+0*(2.;+!_.04M2B@Z-60Y6+"'RF8]=_$=
M+Y(^;<-\-=@=VMZA\;K/SFHXPEA;=M(]P1$48>99[[X6*93H40VF3.CJPJ=Q
MX;/R**R<1^';X>EW24-_4RS@_/#'MU]O+LZMGSLA(-+EK^BS6M6$J(5X%YJK
MF3?S,N\"7A)8P4TO>;)098_/RQX?<\-F1JL\S:/!F_I:*=)#%L;*<EVN;5=V
MX+!34RPS9E,#R#1Z#"/[5PR/W0I?IL*HQ5!N1T(-H%07Q,@,I,H.83D;R@_@
MHQ$R[W#CV8&TNRC$0K*9W8:8_B(;_T1N/Y$Q$S"<PF'@4^#%=URMI!)H4MM]
MIPPT8S*K)MGTQMY55H^R77>*W@*8\3+$L#4HNQFX1A?QH*8G*]3,GCAT[K&*
M@L-NW"@",XX.S!:&/=_#/)@-";18/B1\0$@APC')$V3HXXHN )V4O0F&?V;\
M%J*L=9ECH=^T2CT?%Z#T<TK7R'D^&GM[9(C3,/"TW'<&TKS9;3TY&"7SX*!E
M1UD(71^++ ,%S0-Q*W)V_:'3=WTX%!4B!E/E&EXX=L5M,&(H%&%"\-->JH9:
MR#5&[9#2!H3:V!ZI55?V.7!08)<PG(>MBB*!X-2%($J.#? >?306P\*ID1RK
M4=^B_"B=EP6\RP<-G#H+9T%K37WQ V:$ ;X1* '4E+H!$QAQZ3&<HA,&^ E
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MV6HT+)7K1U?&[#\2-Y2\]>\<;QC%Q0&HC)>N0:7R*/)7QO!B(0#0O._6LB:
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MS'5@2X_MO9WV;OM?S;7/&%N0N-!HU,P8MZG-+5BF'J(:'/6!E G+=9^SU-M
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M*!O324(X(9K9]1T #P[1=2. $QO"\ZR3Q/)E/XCA+;!087FNQW@WAL7@>X3
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ME #&[EL%,&WOM:Q6:WM*4.^V=JT]>)I'4=)'N:PM1U"Z@R2NJ%#VXUT9*@P
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MG/'W==8^_RYXN''B.S]OXI.?B8>S\=BU_?*MK7W&FQ7=P/."!V)KDA,(X"&
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MY_6M"M=?"==M@",'6;[N?I)<.42\3P2[#;@7 4@(*5L,_KON%I\Y.OQVQ6(
MK(#-=\.@C\\V6!PH-;)"Y.T*D9^'R-8H)L=!#!-%/5 U>X$'9PWKC9/09[!/
MF 2T"XW<SK1LFG#V$%14CS64[@G(>\9#N\=:\INML6A<'KG=G4,@>=1+?AE$
M\<9)?^ %0]H"4K7P(QZ[ )SQ4>WMA2SF9XQVY/T&^/>^"^?CVK!86!FNZXOP
M1=<%=/IY$]_XO-!UKGW^33 G8'Z ?*T+V %<#Y"HZ_I@E'3D4MA +6W@<5]R
M-WQ*62>"X"M$5&,P5H_? T*Q=KVQ?O>)7D";YZ'G FZD3Q(Q##B2L#M(%=57
M18VG3N,":"<L(LQKG,<AT+R&[*.PD]B]1T.P"_9@&)'!*( -N2@(@.@,("*<
MS?/(3@]/S8*?;2\ASM 7#O).8B48DX(_Z1FB?^ E\IAQ*G[/78^KN<#J,(Z0
M7I:(X[B1';I]UU>KZ +_)Z8VNH$:.XV1A=S"VD(R8W#)@P!@/L0Y<#A@M<#"
M6 3,UH6WN.0]8-Q$;HPL+\C&52P3EXIO=L* .S!F;MDX04"G:6#JJ0\[IQD
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MDT7P<9#S8@0.T$$1RWST*'K*3!MPWX--+G6MX)\<!%XR] 6M/DCY[M)TO7P
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MS*.H#_(><38B^@3 ?A,Z?@3*%[\4W$NBH8UVXG-]RA#F*ZWK+:LY"$!BGL3
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MPBMV)YLR7>]]U4YB-M2:AKESN[MC[=:H;U-Q535,NY*GUI*CRNW#SO36<[L
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MK1-U53[%619USVBZ,M0I7;=6U&U#?4011I;*(WX#'+U-D<3+3P_G2_);YP:
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MCUW%?,*2R>.P7:GH7OBVPU@)'I;<L_IUI9_;Z6,UGZ=LYU05K2>:!/Q@M/;
MY55O(0MU_'_8%$GN-J#7Z9W60>Y[?=B&'AG\=U2WG:DDSFCB>9,KO9L^0)9$
M&(HWG?QY:8\]_CUMIIVU#_ZJ=BGZ9>GY[1+QDNI_-F;?*>I?$[9*8BH8]UF*
MI\[!-:+>&YYOZ.>U"\735[!Z2U<6\9:'YLL[7]%\VNIRB)/YG?(O4$L#!!0
M   ( &*(H58_!^ &N ,  *<.   1    9#0Y-S0X-&1E>#,Q-"YH=&WM5UEO
MXD@0?H^4_U#R**-=B<M,YI QE@ ["5H(B%AS/#9V@5NQVY;=A+"_?JM] "'7
M9B8SFI66!]1=757]5?57U6[SPAV/+//"Z=G6\9'I#MV18SE?Z^_TQJG9+*8D
M;Y8*8/8G]C?HGP\FH\FLJWVY&+J.9L'Q$2D-4$A,+=,>?H8K]]O(Z6IK[LO
M^-1XSX4&+.1+T=5"7$@M]S6MU"*6+KFHRS@Q6HGL0#F?QU+&42%:Q$+6,_XW
M&OINOF 1#S>&RR/,X!+7,(LC1COU1L/SRZZ6\F5 6YE]R[D-^)Q+4&&!V>Q;
M9G.JXGH(0?OT%2%X>4YR# -,)5]PCTD>"X@7,$VY\'C"0CCC@M&01I,%:6#Z
M',8/KP#1&M9@S+V 80B#!MBQP"43-?!RG!N0 9,&*!![)[7;0$$X.+=[@#3K
MK9AG22=WHNC5ZX^<RE5_,K.=69V8-.I-KQRC&CR)^C!$#0HW7:VEP< 9C:8]
MVQY>GF_G5]/>H)I_&=KN15?36ZT3K< S@TQN0H0N: E;8GV>(KNN<Y%Q'PUV
M$W._5+0KX].375"N?;#X_D2#S^7)4U*V+"@HKS?V3?:7[ACMIQON9AA^]- [
M<(!I" &[04CQAN,:?3ITGD%/B!5Q<89)G$H@LI[%:03FV>32W19VP"76LX1Y
M:(AXG3+"K;?J?S5[9E/I68K@;H"T@"O)O6QLUXZ/AL)KP!\RP.>=O7VCGW[L
MW'59 %(KGSI_=H )/Z=GGE7ZFZD_Q;#_"?LZA&W_AH3MLXQH2IR,-G!-9 G1
M7V*MX.T+&5KRVX]I0Q%+\ @&XX)XM8&5D.D*CX\RR21&U,05GQD%0]U<]>D%
M\TB40AS1K2)CR/7N*0CT,,M8NE$J$;M&4-S?^LQ(YA-XVC-45Y7:0REX//56
M$:D),B<H/ET(%(X70+92?SO[-:98.E$11#P+D?E<+&'-94!EG27HY0"5WX2@
MQ3[%>4-F/LPW1=K2/ \-=<W_ZV+2V]]=38<D/RR"?=+O%\NK5J&EOEB*BK+*
MP:YB/E+)Y'G8KE1T+V+;8:P4[Y?<D_;[1C^VTX=*GA_9+J@J6X\T"7AAM@[
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MNOACV32F>F)9NE<+[XR&@"F$CI:)ED"J"-<MW0B+8K1PXG##JMJ"*(R>33]
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M+$;W9-0&8&G)VK+_:6SL#H) IT%DD U1;(-_FE@+^LVCKPU#&7\ 4$L#!!0
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M.?)TFT0U].:XQ/:[G]Z/)\$"+:$7%7NQJ^+-R.KZ)R<GW6PK@R;1:9+5CTD
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M%U!+ 0(4 Q0    ( &*(H59J!#,F-*@  .CI!@ 0              "  0
M  !D-#DW-#@T9#$P:V$N:'1M4$L! A0#%     @ 8HBA5@5# 4JM P  6@X
M !$              ( !8J@  &0T.3<T.#1D97@S,3,N:'1M4$L! A0#%
M  @ 8HBA5C\'X :X P  IPX  !$              ( !/JP  &0T.3<T.#1D
M97@S,30N:'1M4$L! A0#%     @ 8HBA5IJNAI,J"P  M@L  !D
M     ( !);   &<T.3<T.#1G,#0R-S T,S R-S4P-2YJ<&=02P$"% ,4
M" !BB*%6A] V1-D#  "A$P  $0              @ &&NP  =&UX9"TR,#(R
M,3(S,2YX<V102P$"% ,4    " !BB*%64<\QI6@!  "P @  %0
M    @ &.OP  =&UX9"TR,#(R,3(S,5]C86PN>&UL4$L! A0#%     @ 8HBA
M5G1B:M_B 0  HP8  !4              ( !*<$  '1M>&0M,C R,C$R,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( &*(H5;$@/O$Y0<  "Y4   5
M  "  3[#  !T;7AD+3(P,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4    " !BB*%6
MWYKT=P &  "&0P  %0              @ %6RP  =&UX9"TR,#(R,3(S,5]P
<<F4N>&UL4$L%!@     )  D 3@(  (G1      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
